HONORS AND AWARDS FOR RESEARCH WORK, TEACHING, PUBLIC ENGAGEMENT, AND SERVICE

External Sources

NIDA Career Teachers Award -1974

Chairman and Award Gordon Research Conference on Alcohol-1978

Chairman and Award Gordon Research Conference on Alcohol-1982

Julius Axelrod (Nobel Laurate) Distinguished Speaker Award-1982

Visiting Scientist, Douglas Hospital Research Centre, McGill University-1988

Finalist, Mind Science Foundation "Imagineer Award"-1988

John B. Sullivan Presidential Excellence Award for Treatment and Research-1990

Nursing Health Consultants Outstanding Achievement Award-1990

YMCA Achievement Award-1994

Who’s Who in the World-2009

Lifetime Achievement Award for Scientific Advancement of Addiction Medicine-2011

National Institutes of Addiction Studies.

Best Abstract Award- American Society of Anesthesiology & Pain-2012

Keynote Award –Omics Conference on Addiction Research & Therapy-2012

Keynote Award –Omics Conference on Genetic Syndromes & Gene Therapy -2012

Organizing Program Member -2013 Addiction Research & Therapy Conference, LV 2013 2012

“Epidemiology , Evolutionary Genetics” – Keynote (Orlando, FL)-2013

Addiction Research & Therapy — Keynote (Las Vegas, NV) - 2013

Behavioral Addictions conference – Keynote (Budapest)-2013

President’s Summit Conference – Keynote (Kazakhstan)-2013

Gala Celebrity Event –Scientific Achievement Award -2013

Speaker NADAC Conference (Anaheim, CA)-2013

Chairman Symposia World Congress of Psychiatry(Madrid Spain)  - 2014

Pre-Conference Keynote Addiction Professional Conference(St Louis, MO) -2014

American Society of Addiction Medicine Millennium Lab Award- 2014

Behavioral Addictions conference – Keynote (Budapest)-2015

Neurological Disorders Conference –Baltimore –Keynote-2016

International Society Neurofeedback & Research- Orlando Florida –Keynote-2016

Chair and Founder Gordon Research Conference on Psychiatric Genetics (final Peer Review)-2018

Marquis Who’s Who Lifetime AchievementAward-2018

International Conference on Molecular Genetics & Gene Therapy –Thailand, Keynote                   2018                                                     

World Congress of Mental Health &Neurology Conference –Rome –Keynote-2018

 International Conference on Behavioral Addictions – Cologne Germany  keynote

 Nutritional Approaches to Addictive Behaviors and Mental Health –West Palm-Keynote-2018

International Conference on Behavioral Addictions & Allied Disorders London Keynote-2028

Neurological Disorders Summit-San Francisco   -Keynote -2018

David E Smith Symposia -   San Francisco   -Keynote -2018

National Conference & Addictive Disorders –Workshop –Disneyland-2018

Global Conference on Addiction and Behavioural Health  =Las Vegas  -  2018

Professional Addiction Magazine and Conference webinar on GARS-2018

Article on Obesity and dopamine over 21,000 views 98% rank highest views for all Frontiers papers-2018

Many others not listed

OTHER:

Bigelow Research Fellowship Award, Columbia University-1961

American Foundation for Pharmaceutical Education Fellow Award1966 – 1968

New York Medical College

National Science Foundation Summer Fellowship Award, New York Medical College-1967

Personalities of the South, Listed-1969

American Chemical Society Tour Speaker Plaque Award-1970

National Association of Retail Druggist Citation of Honor-1970

Two‑Thousand Men of Achievement, Listed1971 – 1972

Intercontinental Biographical Association-1973

Career Teachers Award in Substance Abuse – NIDA1974 – 1977

Who's Who in the South and Southwest-1975 & 1982

Personalities of the South, listed in Bicentennial Edition-1976

National Free Clinic Council, Inc., Board of Directors, Southwest Region Representa­tive-1979

Who's Who in the South and Southwest-1979

Citation of Honor, Alamo Area Council of Governments (AACOG)-1979

Certificate of Merit for Substance Abuse Service to the Community-1979

St. Mary's University

Lions Club Speaking Service Award-1979

American Men and Women in Science1979 – 1986

Gordon Research Award-1979 & 1982

Humanitarian Award ‑ Columbian University (College of Pharmacy 20th Year Reunion)-1981

Who's Who in Frontiers of Science and Technology-1984 & 1985

Expert Drug Consultant for Scott Forseman, New Health Text-1985

Contributor to the Definition of Alcoholism for the 1989 World Book Encyclopedia-1985

Marquis Who’s Who inAmerica–Select Premiere -2016

Marquis Who’s Who inAmerica- Expert Resource (Addiction) -     2017

Marquis Who’s Who inAmerica- Lifetime Achievement Award -2017 (Life)

Current Membership

International:

Brain Research Society of Great Britain (Honorary Membership)-1974

International Platform Association-1977

International Biomedical Research Society on Alcoholism (Charter Member)-1981

Founding President United Scientific Group (London, India, USA)-2016

National:

American Foundation for Pharmaceutical Education (Fellow)-1965

American Association for the Advancement of Science (AAAS)-1969

Student Association for Hallucinogens -1970

Research Society of America (RESA)-1970

American Society of Pharmacology and Experimental Therapeutics-1973

Neuroscience Society-1974

American Society of University Professors-1975

Academy of Medical Educators and Substance Abuse (AMESA) Charter member-1976

Society of Medicinal Chemistry-1976

American College of Clinical Pharmacology (Fellow)-1977

Research Society on Alcoholism-1978

Committee of One Thousand (Health)-1979

New York Academy of Science-1979

Honorary Advisory Council – Secular Organization of Sobriety (SOS)-1993

Distinguished Advisory Council – Kids-at-Risk Foundation-1993

American Society for the Advancement of Science-2014

State:

Texas Research Society on Alcoholism (Chart Member)(1980 – Present)

Local:

Bexar County Pharmaceutical Society (Honorary Membership) (1968 – Present)

Holistic Health Association of San Antonio(1979 – Present)

Licensed Pharmacist – New York and Texas (No Longer Licensed) (1979 – Present)

• Editorships/Journal Reviewer Experience
• PEER REVIEWER – EDITORIAL ADVISORY BOARDS (ELECTED):
• Journal Psychoactive Drugs (1976 ‑ Present)
• Clinical Toxicology (1976 ‑ 1983)
• Founder and Editor‑in‑Chief, Substance and Alcohol Actions/ Misuse (Elsevier) (1979 ‑ 1985)
• Functional Neurology (1985 ‑ Present)
• Alcohol and Drug Research (1985 ‑ 1987)
• Addictions, Alert News Letter (1987 ‑ 1991)
• Biogenic Amines  (1987 ‑ Present)
• Journal of Trends in Applied Sciences Research (2006 - Present)
• Gene Therapy & Molecular Biology (2007 - Present)
• Medical Genetics (2007 - Present)
• Associate Editor of Research Notes (BMC) (2008 - Present)
• Theoretical biology & Medical Modeling (2009 - Present)
• Advances in Therapy (2009 - Present)
• Journal Of Obesity (open access) (2009 - Present)
• IIOAB Journal (2010 - Present)
• IIPOAB Letters (2012 - Present)
• Journal of Genetic Syndromes & Gene Therapy EIC (2012 - 2015)
• Journal of Genetic Diseases and Genetic Reports EIC (2012 - 2015)
• Functional Foods in Health and Chronic Diseases (2011 - Present)
• World Class Cases (2012 - Present)
• Behavioral Addictions (2013 - Present)
• Journal of Addiction & Research Therapy (2013 - Present)
• Frontiers in Neuroscience (2013 - Present)
• Science Impact Journal (2012 - Present)
• Jacob Alcohol & Drug Abuse (2014 - Present)
• Journal of Addiction Therapy &Research (EIC2014 - 2015)
• Human Pharmacology, Genomics & Behavior EIC (2014-Present)
• Journal of Reward Deficiency Syndrome (RDS)-Editor –in-Chief (2015-Present)
• Neuroimaging in Psychiatry & Neurology (co –editor in Chief) (2015 -Present)
• Addiction Genetics (Co-Editor in Chief) 2015
• Clinical Insights in Medical Reports & Case Studies (2015-Present)
• Substance Use Misuse (editorial Board) (2015-Present)
• Addiction Therapy and Rehabilitation (editorial Board) 2016
• Health (editorial Board) (2015-Present)
• Journal of Forensic Sciences (editorial Board) (2016-Present)
• Clin MedRev & Case Reports (Editorial Board) (2016 –Present)
• Frontiers in Biosciences (Editorial Board)2017

PUBLICATIONS

Peer-Reviewed Publications:

1. Blum, K.  The effect of dopamine and other catecholamines on neuromuscular transmission.  Arch. Int. Pharmacodyn. Ther. 181:297‑306, October, 1969.
2. Blum, K. Effects of chlordiazepoxide and pentobarbital on conflict behavior in rats. Psychophar­macologia 17(5):391‑8, 1970.
3. Blum, K., Ryback, R.S. and Geller, I.  Effects of vodka and bourbon on sleeping time in mice.  Q. J. Stud. Alcohol (Suppl) 5:62‑6, May, 1970.
4. Geller, I. and Blum, K.  The effects of 5‑HTP on para‑chlorphenylalanine (p‑CPA) attenuation of "conflict" behavior.   Eur. J. Pharmacol. 9(3):319‑24, March, 1970. 
5. Geller, I., Campbell, N.D. and Blum, K.  Protection against acute alcoholic intoxication with diethanolamine ‑rutin.  Res. Commun. Chem. Pathol. Pharmacol. 1(3):383‑94, May, 1970.
6. Blum, K., Seifter, E. and Seifter, J.  The pharmacology of d‑ and 1‑choline and d‑ and 1‑acetylcarnitine.  Comparison with choline and acetylcholine. J. Pharmacol. Exp. Ther. 178(2):331‑8, August, 1971.
7. Blum, K., Geller, I. and Wallace, J.E.  Interaction effects of ethanol and pyrazole in laboratory rodents.  Br. J. Pharmacol. 43(1):67‑73, September, 1971.
8. Geller, I., Hartmann, R. and Blum, K.  Effects of nicotine, nicotine mono‑methiodide, lobeline, chlordiaze­poxide, meprobamate and caffeine on a discrimination task in laboratory rats.  Psychopharma­cologia 20(4):355‑65, 1971.
9. Payte, J.T., Wallace, J.E. and Blum, K.  Hydrolysis:  A requisite for morphine detection in urine.  Curr. Ther. Res. 13(6):412‑6, June, 1971.
10. Blum, K., Ryback, R.S. and Geller, I. Effects of vodka and bourbon on lever‑ pressing behavior of mice.  Curr. Ther. Res. 14(2):95‑8, February, 1972. 
11. Blum, K., Wallace, J.E. and Geller, I.  Synergy of ethanol and putative neurotrans­mitters:  Glycine and serine.  Science 176(32):292‑4, April 21, 1972.
12. Blum, K., Merritt, J.H., Wallace, J.E., Owen, R., Hahn, J.W. and Geller, I. Effects of catecholamine synthesis inhibition on ethanol narcosis in mice. Curr. Ther. Res. 14(6):324‑9, June, 1972.
13. Blum, K., Huizenga, C.G., Ryback, R.S., Johnson, D.K. and Geller, I.  Toxicity of diethanolamine in mice. Toxicol. Appl. Pharmacol. 22(2):185‑85, June, 1972. 
14. Blum, K., Wallace, J.E., Ryback, R.S. and Geller, I.  Diethanolamine: A possible weak agonist ‑antagonist to ethanol. Eur. J. Pharmacol. 19(2):218‑22, August, 1972. 
15. Geller, I., Hartmann, R.J. and Blum, K.  The effects of low‑dose combinations of D‑amphet­amine and cocaine on experimentally induced conflict in the rat.  Curr. Ther. Res. 14(4):220‑4, April, 1972.
16. Wallace, J.E., Biggs, J.D. and Blum, K. Gas‑liquid and thin‑layer chromatographic determination of morphine in biologic specimens. Clin. Chem. Acta. 36(1):85‑91, January, 1972.
17. Wallace, J.E., Biggs, J.D., Merritt, J.H., Hamilton, H.E. and Blum, K.  A sensitive thin‑layer chromatographic technique for determining morphine in urine. J. Chromatogr. 71(1):35‑40, August 23, 1972.
18. Wallace, J.E., Hamilton, H.E., Payte, J.T. and Blum, K.  Sensitive spectrophotometric method for determining methadone in biological specimens.  J. Pharm. Sci. 61(9):1397‑400, September, 1972.
19. Wallace, J.E., Ladd, S.L. and Blum, K.  Determination of propoxyphene in biological materials by ultraviolet spectrophotometry and gas chromatography.  J. Forensic Sci. 17(1):164‑73, January, 1972.
20. Blum, K., Merritt, J.H., Reiter, R.J. and Wallace, J.E.  A possible relationship between the pineal gland and ethanol preference in the rat.  Curr. Ther. Res. 15(1):25‑30, January, 1973.
21. Blum, K., Calhoun, W., Merritt, J. and Wallace J.E.  L‑DOPA:  Effect on ethanol narcosis and brain amines in mice.  Nature 242(397):407‑9, April 6, 1973. 
22. Blum, K., Calhoun, W., Wallace, J.E., Merritt, J.H. and Geller, I.  Soporific action of ethanol in mice:  Possible role of biogenic amines.  Pharmacol. Biochem. Behav. 1(3):271‑6, May‑June, 1973.
23. Blum, K., Calhoun, W., Merritt, J.H. and Wallace, J.E.  Synergy of ethanol  and alcohol‑like metabolites:  Tryptophol and 3,4‑dihydroxyphenylethanol.  Pharmacology 9(5):294‑9, 1973.
24. Wallace, J.E., Biggs, J.D., Hamilton, H.E., Foster, L.L. and Blum, K.  UV spectrophotometric method for determination of phenacetin in biological specimens.  J. Pharm. Sci. 62(4):599‑601, April, 1973.
25. Reiter, R.J., Blum, K., Wallace, J.E. and Merritt, J.H.  Effect of the pineal gland on alcohol consumption by congenitally blind male rats.  Q. J. Stud. Alcohol 34(3):937‑9, September, 1973.
26. Blum, K., Hudson, K. and Wallace, J.E. Tetrahydrocannabinol blockade of alcohol‑induced withdrawal symptoms in mice.  2nd International Symposium on Drug Addiction, New Orleans, Louisiana, March 7‑9, 1973.
27. Blum, K., Eubanks, J.D., Wiggins, B., Tabor, R.G., Wallace, J.E. and Friedman, R.N.  The effects of acceleration on ethanol‑induced narcosis in mide. IRCS 2:1468, 1974.
28. Blum, K., Wallace, J.E. and Eubanks, J.D.  Effects of alanine and disulfiram on blood acetaldehyde and ethanol in rats. IRCS 3:332, 1974.
29. Blum, K., Wallace, J.E. and Friedman, R.N.  Reduction of acute alcoholic intoxication by alpha amino acids:  Glycine and serine.  Life Sci. 14(3): 557‑65, February 1, 1974.
30. Blum, K. and Wallace, J.E.  Effects of catecholamine synthesis inhibition on ethanol‑induced withdrawal symptoms in mice.  Br. J. Pharmacol. 51(1):109‑11, May, 1974.
31. Blum, K., Wallace, J.E., Calhoun, W., Tabor, R.G. and Eubanks, J.D. Ethanol narcosis in mice: Serotonergic involvement. Experientia 30(9):1053‑4, September 15, 1974.
32. Hamilton, H.E., Wallace, J.E. and Blum, K. Improved methods for quantitative determination of methadone.  J. Pharm. Sci. 63(5):741‑5, May, 1974.
33. Wallace, J.E., Hamilton, H.E., Riloff, J.A. and Blum, K. Spectrophotometric determination of ethchlorvynol in biologic specimens.  Clin. Chem. 20(2): 159‑62, February, 1974.
34. Wallace, J.E., Blum, K., Foster, K. and Eubanks, J.D. Drug identification:  Spectroscopy, colorimetry and flurometry.  J. Pharmaceut. Sci. 63(2):741, 1974.
35. Wallace, J.E., Hamilton, H.E. and Blum, K.  Microdetermination of dephenylhydantoin in serum and plasma by ultraviolet spectrophotometry.  J. Pharm. Sci. 63:1795, 1974.
36. Wallace, J.E., Hamilton, H.E., Farquhar, J.K., Everhart, B.E. and Blum, K.  Comments on the determination of dephenylhydantoin.  Clin. Chem. 20:515, 1974.
37. Wallace, J.E., Hamilton, H.E., Blum, K. and Petty, C. Determination of morphine in biologic fluids by electron capture gasliquid chromatography. Anal. Chem. 46(14):2107‑11, December, 1974.
38. Wallace, J.E., Blum, K. and Singh, J.M. Determination of drugs in biologic specimens review. Clin. Toxicol. 7(5):477‑95, 1974.
39. Reiter, R.J., Blum, K., Wallace, J.E. and Merritt, J.H.  Pineal gland: Evidence for an influence on ethanol preference in male Syrian hamsters. Comp. Biochem. Physiol. (A) 47(1):11‑6, January, 1974.
40. Wallace, J.E., Blum, K. and Singh, J.  Determination of drugs in biological specimens.  Toxicol. Annals 2:167, 1975.
41. McDonald, L.K., Maddux, J.F. and Blum, K.  Fetal consequences of chronic methadone administration to pregnant rats:  Methodological problems. Curr. Ther. Res. 17(3):308‑17, March, 1975.
42. Hamilton, H.E., Wallace, J.E. and Blum, K. Spectrophotometric and gas‑liquid chromatographic determination of amitriptyline. Anal. Chem. 47(7):1139‑43, June, 1975.
43. Wallace, J.E., Hamilton, H.E., Goggin, L.K. and Blum, K. Determination of amitriptyline at nanogram levels in serum by electron capture gas‑liquid chromatography. Anal. Chem. 47(9):1516‑9, August, 1975.
44. Wallace, J.E., Hamilton, H.E., Schwertner, H., King, D.E., McNay, J.L. and Blum, K. Thin‑layer chromatographic analysis of cocaine and benzoylecgonine in urine. J. Chromatogr. 114(2):433‑41, November, 1975.
45. Blum, K., Wallace, J.E. and Eubanks, J.D.  Effects of naloxone on ethanol withdrawal:  Preference and narcosis.  Pharmacologist 17(197), 1975. 
46. Blum, K., Eubanks, J.D., Wallace, J.E., Schwertner, H.A. and Futterman, S.  Possible rationale for differential chemotherapy of depression in humans: A review of the biogenic amine hypothesis, Part I.  J. Psychedelic Drugs, 8(3): 223‑234, 1976.
47. Blum, K.  Depressive states induced by drugs of abuse: Clinical evidence, theoretical mechanism(s) and proposed treatment, Part II. J. Psychedelic Drugs,  8(3): 235‑262, 1976.
48. Wallace, J.E., Hamilton, H.E., Goggin, K.K. and Blum, K. Determination of chlorprothixine by electron capture gas‑liquid chromatography. J. Forensic Sci., 1976. 
49. Blum, K., Eubanks, J.D., Wiggins, B. and Wallace, J.E. Morphine withdrawal reactions in male and female mice.  Am. J. Drug. Alcohol Abuse 3(2):363‑8, 1976. 
50. Blum, K., Eubanks, J.D., Wallace, J.E., Schwertner, H. and Morgan, W.W.  Possible role of tetrahydroiso­quinoline alkaloids in postalcohol intoxication states. Ann. NY Acad. Sci. 273:234‑46, 1976.
51. Blum, K., Wallace, J.E., Schwertner, H.A. and Eubanks, J.D. Enhancement of ethanol‑induced withdrawal convulsions by blockade of 5‑hydroxytryptamine receptors. J. Pharm. Pharmacol. 28(11):832‑5, November, 1976.
52. Blum, K., Eubanks, J.D., Wallace, J.E. and Hamilton, H. Enhancement of alcohol withdrawal convulsions by haloperidol. Clin. Toxicol. 9(3):427‑34, 1976.
53. Blum, K., Eubanks, J.D., Wallace, J.E. and Schwertner, H.A. Suppression of ethanol withdrawal by dopamine.  Experientia 32(4):493‑5, April 15, 1976. 
54. Blum, K., Wallace, J.E., Schwertner, H.A. and Eubanks, J.D.  Morphine suppression of ethanol withdrawal in mice.  Experientia 32(1):79‑82, January 15, 1976. 
55. Blum, K., Meyer, E., Futterman, S., Wallace, J.E. and Schwertner, H.A.  Possible neurochemical mechanisms of ethanol dependence in mice.  Pharmacologist 18:681, 1976. 
56. Blum, K. and Futterman, S.L. Drugs: Have it your way. J. Psychedelic Drugs 9(1):81‑2, 1977.
57. Blum, K., Futterman, S.L. and Pascarosa, P. Peyote, a potential ethnopharmacologic agent for alcoholism and other drug dependencies: Possible biochemical rationale. Clin. Toxicol. 11(4):459‑72, 1977.
58. Marshall, A., Hirst, M. and Blum, K. Analgesic effects of 3‑carboxysalsolinol alone and in combination with morphine. Experientia 33(6):754‑5, June 15, 1977.
59. Schwertner, H.A., Blum, K., Wallace, J.E. and Eubanks, J.D. Alterations in brain electrolytes during acceleration in mice. Aviat. Space Environ. Med. 48(8):705‑7, August, 1977.
60. Blum, K., Wallace, J.E., Schwertner, H.A., Meyer, E. and Morgan, W.W. Central super sensitivity to norepinephrine and amphetamine following brain chemical sympathectomy by 6‑hydroxy­dopamine.  Life Sci. 20(10):1705‑13, May 15, 1977. 
61. Wallace, J.E., Hamilton, H.E., Shimek, E.L., Jr., Schwertner, H.A. and Blum, K.  Determination of primidone by electron‑capture gas chromatography.  Anal. Chem. 49(7):903‑6, June, 1977.
62. Hamilton, M.G., Blum, K. and Hirst, M.  Ethanol dependence:  Modification by administration of calcium gluconate and phenoxybenzamine alcoholism.  Clin. and Exp. Res. 1(2):153, 1977.
63. Blum, K., Hamilton, M.G., Meyer, E.K., Hirst, M. and Marshall, A. Isoquinoline alkaloids as possible regulators of alcohol addiction (Letter). Lancet 1(8015):799‑800, April 9, 1977.
64. Blum, K., Wallace, J.E., Meyer, E. and Schwertner, H.A. Intensification of amphetamine‑induced excitation by methysergide, a sertonergic receptor blocker. Experientia 33(2):213‑5, February 15, 1977.
65. Blum, K. and Briggs, A.H. Effects of delta9 tetrahydrocannabinol (delta9‑THC) on amphetamine‑aggregate toxicity in mice. Curr. Ther. Res. 21(2):241‑4, February, 1977.
66. Blum, K., Futterman, S., Wallace, J.E. and Schwertner, H.A. Naloxone‑induced inhibition of ethanol dependence in mice.  Nature 265(5589):49‑51, January 6, 1977. 
67. Pollock, S.H. and Blum, K. Metabolic stereospecificity of opiate agonist and antagonist drugs.  In:  Alcohol and Opiates: Neurochemical and Behavioral Mechanisms.  Editor:  K. Blum. Academic Press, New York, pp. 359, 1977.
68. Blum, K., Newmeyer, J. Inaba, D. Whitehead, C., Smith, D.E. Acupuncture as a common treatment modality in drug and alcohol dependence: Possible neurochemical rationale. J. Psychedelic Drugs, 10: 105‑115, 1978.
69. Blum, K., Hamilton, M.G., Hirst, M. and Wallace, J.E.  Putative role of isoquinoline alkaloids in alcoholism: A link to opiates. Alcoholism: Clin. Exp. Res. (NY) 2(2):113‑20, April, 1978.
70. Hamilton, M.G., Blum, K. and Hirst, M. Identification of an isoquinoline alkaloid after chronic exposure to ethanol.  Alcoholism: Clin. Exp. Res. (NY) 2(2):133‑7, April, 1978.
71. Carter, P., Wallace, J.E. and Blum, K. Improved ultraviolet spectrophotometry of serum theophylline. Clin. Chem. 24(2):360‑1, February, 1978.
72. Schwertner, H.A., Wallace, J.E. and Blum, K. Improved ultraviolet spectrophotometry of serum theophylline.  Clin. Chem. 24:360‑361, 1978.
73. Hamilton, M.G., Hirst, M. and Blum, K. Opiate‑like activity of salsolinol on the electrically stimulated guinea pig ileum. Life Sci. 25(26):2205‑10, December 24, 1979.
74. Verebey, K. and Blum, K.  Alcohol euphoria:  Possible mediation via endorphinergic mechanisms.  J. Psychedelic Drugs 11(4):305‑11, October‑December, 1979.
75. Blum, K., Eubanks, J.D., Elston, S.F.A. and Briggs, A.H.  Differential brain receptor stimulation by norepinephrine and serotonin:  Possible rationale for differential chemotherapy or depression in humans.  Acupuncture and Electrotherapeutic Res. 4:185‑94, 1979.
76. Blum, K., Briggs, A.H., Elston, S.F. and DeLallo, L.  Psychogenetics of drug seeking behavior (Letter) Subst. Alcohol Actions Misuse 1(3):255‑7, 1980.
77. Blum, K., Cull, D.L., Briggs, A.H.  An improved technique for the induction of barbiturate dependence in mice.  J. Pharmacol. Methods 3(1):89‑92, January, 1980.
78. Blum, K., Briggs, A.H., DeLallo, L. and Elston, S.F.  Genotype dependent responses to ethanol and normorphine on vas deferens of inbred strains of mice.  Subst. Alcohol Actions Misuse 1(5‑6):459‑65, 1980.
79. Blum, K., Briggs, A.H., DeLallo, L., Elston, S.F. and Hirst, M.  Naloxone antagonizes the action of low ethanol concentrations on mouse vas deferens.  Subst. Alcohol Actions Misuse 1(4):327‑34, 1980.
80. Dalterio, S., Blum, K., DeLallo, L., Sweeney, C., Briggs, A. and Bartke, A.  Perinatal exposure to delta 9‑THC in mice:  Altered enkephalin and norepinephrine sensitivity in vas deferens.  Subst. Alcohol Actions Misuse 1(5‑6): 467‑71, 1980.
81. Hamilton, M.G., Blum, K. and Hirst, M. In vivo formation of isoquinoline alkaloids: Effect of time and route of administration of ethanol. Adv. Exp. Med. Biol. 126:73‑86, 1980.
82. Blum, K.  "The Psychogenetics of Drug Seeking Behavior."  FIDIA Laboratories, Aldana, Terne, Italy, June, 1980.
83. Blum, K., Elston, S.F., Schwertner, H., DeLallo, L. and Briggs, A.H.  A rapid method to evaluate acute ethanol intoxication in mice.  Pharmacol. Biochem. Behav. 14(6):835‑8, June, 1981.
84. Blum, K., Elston, S.F.A., DeLallo, L. and Briggs, A.H.  A rapid method for the evaluation of ethanol intoxication in mice.  Pharmacol. Biochem. and Behavior, 14:835‑8, 1981.
85. Blum, K., Briggs, A.H., Elston, S.F. and DeLallo, L.  Ethanol preference as a function of genotypic levels of whole brain enkephalin in mice.  Toxicol. Eur. Res. 3(5):261‑2, September, 1981.
86. Blum, K., Briggs, A.H. and Cull, J.G.  Holism:  A social pharmacological approach to drug‑seeking behavior.  J. Psychoactive Drugs 13(4):369‑71, October­‑December, 1981.
87. Dalterio, S., Bartke, A., Blum, K. and Sweeney, C.  Marihuana and alcohol:  Perinatal effects on development of male reproductive functions in mice.  Prog. Biochem. Pharmacol. 18:143‑54, 1981.
88. Blum, K.  Evidence for the psychogenetic theory of drug seeking behavior.  Symposium: Ethanol, Nucleic Acid and Protein Synthesis in Brain and Other Organs. Subs. Alco. Act./Misuse 2(4):196, 1981.
89. Blum, K., Briggs, A.H., DeLallo, L., Elston, S.F. and Ochoa, R. Whole Brain methionine‑enkephalin of ethanol‑avoiding and ethanol‑preferring C57BL mice. Experientia 38(12):1469‑70, December 15, 1982.
90. Wallace, J.A. and Blum, K. An evaluation of the TRI dipstick test for the detection of drugs of abuse in urine.  Subst. Alcohol Actions Misuse 3(1‑2): 129‑32, 1982.
91. Blum, K., Briggs, A.H. and DeLallo, L. On the mechanism of methadone‑induced alcohol consumption in humans (Letter). Subst. Alcohol Actions Misuse 3(1‑2): 1‑4, 1982.
92. Blum, K., DeLallo, L., Briggs, A.H. and Hamilton, M.G. Opioid responses of isoquinoline alkaloids (TIQs). Prog. Clin. Biol. Res. 90:387‑98, 1982.
93. Blum, K., Briggs, A.H., Elston, S.F., DeLallo, L., Sheridan, P.J. and Sar, M.  Reduced leucine‑enkephalin──like immunoreactive substance in hamster basal ganglia after long‑term ethanol exposure.  Science 216(4553):1425‑7, June 25, 1982.
94. Elston, S.F., Blum, K., DeLallo, L. and Briggs, A.H.  Ethanol intoxication as a function of genotype dependent responses in three inbred mice strains.  Pharmacol. Biochem. Behav. 16(1):13‑5, January, 1982.
95. Blum, K., Briggs, A.H. and Verebey, A.K.  The pharmacology of addictive drugs:  Similarities and differences.  In:  Perspectives in Alcohol and Drug Abuse:  Similarities and Differences.  Editor:  J. Solomon, 1982. Academic Press, New York.
96. Blum, K. Special Guest Invitation of Correo Medico Magazine Conference on Drug Dependence.  "The Psychogenetic Theory of Drug Seeking Behavior," Milan, Italy, 1982.
97. Blum, K.  Alcohol and central nervous system peptides. Subst. Alcohol Actions Misuse 4(2‑3):73‑87, 1983.
98. Blum, K., Elston, S.F., DeLallo, L., Briggs, A.H. and Wallace, J.E. Ethanol acceptance as a function of genotype amounts of brain (Met)enkephalin.  Proc. Natl. Acad. Sci. USA 80(21):6510‑2, November, 1983. 
99. Blum, K., Briggs, A.H. and DeLallo, L.  Clonidine enhancement of ethanol withdrawal in mice.  Subst. Alcohol Actions Misuse 4(1):59‑63, 1983.
100. Blum, K., Dalterio, S., Briggs, A.H., DeLallo, L.J. and Hall, C.W.  Super‑sensitivity to norepinephrine induced by prenantal exposure to ethanol.  Eur. J. Pharmacol. 106(2):415‑7, November, 13, 1984.
101. Blum, K., Gaskill, H., DeLallo, L., Briggs, A.H. and Hall, W.  Methionine enkephalin as a possible neuromodulator of regional cerebral blood flow.  Experientia 41(7):932‑3, July 15, 1985.
102. Blum, K. and Wallace, J.E.  A commentary on the biochemical pathogenesis of alcohol‑induced depression.  J. Psychoactive Drugs, 1985 18(2):161‑2, 1986.
103. Blum, K., Wallace, J.E., Briggs, A.H. and Trachtenberg, M.C.  Evidence for the "Genotype" theory in alcohol seeking behavior:  A commentary.  Alch. Drug Res. 6:455‑61, l986.
104. Blum, K., Trachtenberg, M.L. "Neurochemistry and Alcohol Craving."  Calif. Soc. Treat. Alc. Other ­Drug Dependence News 13(2):1‑7, 1986.
105. Blum, K. Alcoholism:  Scientific Basis and Chemotherapeutic Control. Dental School Quarterly (UTHSC) 2(1):1‑5, 1986.
106. Blum, K., Wallace, J.E., Briggs, A.H., DeLallo, L. and Trachtenberg, M.C. Enkepha­linase inhibition by thiorphan and subsequent response to ethanol, normorphine and enkephalins on mouse vas deferens.   Functional Neurology, 1:156‑64, 1986.
107. Blum, K., and Topel, H.  Opioid peptides and alcoholism:  Genetic deficiency and chemical management.  Func. Neurol. 1:71‑83, 1986.
108. Blum, K., Trachtenberg, M.C.  New insights into the causes of alcoholism.  Prof. Counselor 1(5):33‑36, 1987.
109. Blum, K., DeLallo, L., Briggs, A.H. and Hall, C.W.  Salsolinol and D‑Ala2‑MeT5­‑Enkephalinamide on guinea pig ileum:  Possible opioid agonist/antagonist interaction.  Biogenic Amines 4(5):193‑198, 1987.
110. Blum, K., Briggs, A.H., Wallace, J.E., Hall, C.W., Trachtenberg, M.C. Regional brain (MET) ‑ enkephalin in alcohol‑preferring and non‑alcohol‑preferring inbred strains of mice.  Experientia 43:408‑410, 1987.
111. Blum, K., Wallace, J.E., Trachtenberg, M.C.  Enkephalinase inhibition:  Regulation of ethanol intake in genetically predisposed mice.  Alcohol 4(6): 449‑456, 1987.
112. Trachtenberg, M.C., Blum, K.  Alcohol and opioid peptides:  Neuroparmacological rationale for physical craving of alcohol.  Am. J. Drug Abuse 13(3):365‑372, 1987.
113. Blum, K., Trachtenberg, M.C., Elliott, C.E., Dingler, M.L., Sexton, R.L., Samuels, A.I. and Cataldie, L.  Enkephalinase inhibition and precursor amino acid loading improves inpatient treatment of alcohol and poly drug abusers:  Double‑blind placebo‑controlled study of the nutritional adjunct SAAVE  Alcohol 5:481‑493, 1988.
114. Blum, K. and Trachtenberg, M.C.  Alcoholism: Scientific basis of a neuropsycho­genetic disease. Intl. J. Addict. 23:781‑796, 1988.
115. Blum, K., Trachtenberg, M.C. and Ramsey, J.C.  Improvement of inpatient treatment of the alcoholic as a function of neurotransmitter restoration:  A pilot study.  Intl. J. Addict. 23:991‑998, 1988.
116. Trachtenberg, M.C. and Blum, K.  Improvement of cocaine‑induced neuromodulator deficits by the neuronutrient Tropamine'  J. of Psycho. Drugs 20:315‑331, 1988.
117. Blum, K. and Trachtenberg, M.C.  Neurogenetic deficits caused by alcoholism:  Restoration by SAAVETM, a neuronutrient intervention adjunct.  J. of Psycho. Drugs 20:297‑313, 1988.
118. Blum, K., Briggs, A.H.  Opioid peptides and genotypic responses to ethanol.  Biogenic Amines 5:527‑533, 1988.
119. Blum, K.  Narcotic antagonism of seizures induced by a dopamine‑derived tetra­hydroiso­quinoline alkaloid.  Experientia 44:751‑753, 1988.
120. Blum, K., Allison, D., Trachtenberg, M.C., Williams, R.W. and Loeblich, L.A.  Reduction of both drug hunger and withdrawal against advice rate of cocaine abusers in a 30‑day inpatient treatment program by the neuronutrient Tropamine'  Curr. Ther. Res. 43:1204‑1214, 1988.
121. Blum, K.  A commentary on neurotransmitter restoration as a common mode of treatment for alcohol, cocaine and opiate abuse.  Integr. Psych. 6:199‑204, 1989.
122. Blum, K., Briggs, A.H., Trachtenberg, M.C. Ethanol ingestive behavior as a function of central neurotransmis­sion. (Review). Experientia 45:444‑452, 1989.
123. Blum, K.  Multi‑authored review on molecular basis of alcoholism.  Molecular mechanism of intracellular ethanol action. Experientia 45:406, (7 reviews), 1989.
124. Blum, K. Neuro‑nutrition as an adjunct to therapy for addictive disease.  The Nutrition Report. I(6), 1989.
125. Blum, K., Briggs, A.H., Delallo, L., Hall, C.W., and Parvez, S.H.  Potentiation of the inhbibitory action of methionine ‑ enkephalamide by low ethanol concentrations on mouse vas biferens. Biogenic Amines 7(3):249‑255, 1990
126. Blum, K., Trachtenberg, M.L., and Cook, D.W.  Neuronutrient effects on weight loss in carbohydrate bingers:  An open clinical trial.  Current Therapeutic Research.  48(2):217‑233, 1990.
127. Blum, K., Noble, E.P., Sheridan, P.J., Montgomery, A, Ritchie, T., Jagadeeswaran, P., Nosam, H., Briggs, A.H., and Cohn, J.B.  Allelic Association of human dopamine D2 receptor gene in alcoholism.  JAMA. 263(15):2055‑2060, 1990.
128. Blum, K. and Noble, E.P. Allelic association of human dopamine D2 receptor gene in alcoholism (Reply).  JAMA 264(14):1807‑1809.  (Letter)
129. Brown, R.J., Blum, K. and Trachtenberg, M.C. Neurodynamics of relapse prevention: A neuronutrient approach to outpatient DUI offenders.  J. Psychoactive Drugs.  22(2):173‑187, 1990.
130. Braverman, E.R., Blum, K., and Smayda, R.J.  A commentary on brain mapping in 60 substance abusers:  Can the potential for drug abuse be predicted and prevented by treatment.  Cur. Therap. Res.  48(4):569‑ 585, 1990.
131. Braverman, E., Smith, R., Smayda, R., and Blum, K.  Modification of P300 amplitude and other e electrophysiological parameters of drug abuse by cranial electrical stimulation.  Cur. Therap. Res. 48(4):586‑596, 1990.
132. Blum, K., Rassner, M. and Payne, J.E.  Neuronutrient therapy for compulsive disease:  Rationale and clinical evidence.  Addiction and Recovery 10(2):12‑16, 1990.
133. Blum, K.  The "Alcoholic" Gene, Professional Counselor. Sept/Oct 39‑47, 1990.
134. Blum, K.  The background for abuse, Sixth Edition of the Psychiatric Knowledge and Skills Self‑Assessment Program VI.  (PKSAP VI), pp 43‑59, 1990.
135. Noble, E.P., Blum, K., Ritchie, T., Montgomery, A., and Sheridan, P.J.  Allelic association of the dopamine D2 receptor gene with receptor binding characteristics in alcoholism.  Arch. Gen. Psyc.  48:648‑654, 1991.
136. Noble, E.P. and Blum, K.  Rebuttal Letter:  Population and pedigree studies reveal a lack of association between the dopamine D2 receptor gene with alcoholism.  JAMA 265(20):2667‑2668. 1991. 
137. Blum, K., Noble, E.P., Sheridan, P.J., Finley, O., Montgomery, A., Ritchie, T., Ozkaragoz, T., Fitch, R.J., Sadlack, F., Sheffield, D., Dahlmann, T., Halbardier, S., and Nogami, H.  Association of the A1 allele of the D2 dopamine receptor gene with severe alcoholism.  Alcohol 8, 1991.
138. Kaats, G.R., Wise, J.A., Blum, K., Morin, R.J., Adelman, J.A., Craig, J. and Croft, H.A. The short‑term therapeutic efficacy of treating obesity with a plan of improved nutrition and moderate caloric restriction.  Cur. Thera. Res. 51:261‑274, 1992.
139. Blum, K., Noble, E.P., Sheridan, P.J., Montgomery, A., Ritchie, T., Ozkaragoz, T., Fitch, R.J., Wood, R., Finley, O. and Sadlack, F.  Genetic predisposition in alcoholism:  association of the D2 dopamine receptor TaqI B1 RFLP with severe alcoholics. Alcohol 10:59‑67, 1993.
140. Noble, E.P., Blum, K., Khalsa, M.E., Ritchie, T., Montgomery, A., Wood, R.C., Fitch, R.J., Ozkaragoz, T., Sheridan, P.J., Anglin, D., Paredes, A., Treiman, L.J. and Sparkes, R.S.  Allelic association of the D2 dopamine receptor gene with cocaine dependence. Alcohol and Drug Dependence 33:271-285, 1993.
141. Noble, E.P. and Blum, K.  Alcoholism and the D2 dopamine receptor gene. Letter to JAMA 270:1547, 1993.
142. Blum, K. Braverman, E.R., Dinardo, M.J., Wood, R.C. and Sheridan, P.J., Prolonged P300 latency in a neuropsychiatric population with the D2 dopamine receptor A1 allele,  Pharmacogenetics, 4:313-322, 1994.
143. Gejman, P.V., Ram, A., Gelernter, J., Friedman, E., Cao, Q., Pickar, D., Blum, K., Noble, E.P., Kranzler, H.R., O'Malley, S., Hamer, D.H., Whitsitt, F., Rao, P., DeLisi, L.E., Virkkunien, M., Linnoila, M., Goldman, D. and Gershon, E.S.  No structural mutation in the dopamine D2 receptor gene in alcoholism or schizophrenia: Analysis using denaturing gradient gel electrophoresis. JAMA 271: 204-208, 1994.
144. Noble, E.P., Syndulko, K., Fitch, R.J., Ritchie, T., Bohlman, M.C., Guth, P., Sheridan, P.J., Montgomery, A., Heinzmann, C., Sparkes, R.S. and Blum, K., D2 dopamine receptor Taq I alleles in medically ill alcoholic and nonalcoholic patients.  Alcohol & Alcoholism, 29:729-744, 1994.
145. Blum, K., Noble, E.P., Balducci, G., Pasculli, E. and Ceccanti, M.  Psychoneuro­genetic and behavioral aspects of alcoholism.  The cascade theory of reward and the role of tetrahydro-isoquinoline (TIQs): the alcohol-opiate linkage, Alcologia 6: 89-98, 1994.
146. Blum, K. and Noble, E.P. The sobering D2 story. Science, 265, 1346, 1994.
147. Blum K., Braverman ER, Dinardo M., Wood R., Sheridan P., “Prolonged P300 Latency in a Neuropsychiatric Population with the D2 Dopamine Receptor A1 Allele," American Psychiatric Electrophysiology Association, 2nd annual meeting, Philadelphia, PA., May 20, 1994.  Pharmacogenetics, 1994; 4: 313-322.
148. Defrance J., Hymel C., Trachtenberg M., Ginsberg L., Braverman ER, Blum K., “Enkephalinase-inhibition and Precursor Amino Acid Loading Enhances Attention Processing and P300 in Healthy Humans," American Psychiatric Electrophysiology Association, 2nd annual meeting, Philadelphia, PA., May 20, 1994.
149. Blum, K., Braverman, E.R., Wood, R.C. and Sheridan, P.J.  Increased prevalence of the Taq I A1 allele of the Dopamine D2 receptor gene in obesity with comorbid polysubstance abuse.  Pharmacogenetics 6, 297-305, 1995
150. Blum, K., Sheridan. P.J., Wood, R.C., Braverman, E.R., Chen, T.J.H.and Comings, D.E.  Dopamine D2 receptor gene variants: association and linkage studies in impulsive-addictive-compulsive behavior.  Pharmacogenetics 5:121-141, 1995.
151. Blum, K., Sheridan, P.J., Wood, R. and Braverman, E.R. Dopamine D2 receptor gene polymorphisms in Scandinavian chronic alcoholics: a reappraisal.  Eur. Arch. Psychiatry Clin. Neurosci 244: 50-52, 1995.
152. Blum, K., Wood, R.C., Braverman, E.P., Chen, T.J.H. and Sheridan, P.J.  D2 dopamine receptor gene as a predictor of compulsive disease: Bayes' theorem. Functional Neurology: 10(1):37-44, 1995.
153. Blum, K., Sheridan, P.J., Wood, R. and Braverman, ER, “Dopamine D2 receptor gene polymorphisms in Scandinavian chronic alcoholics:  a reappraisal.”  Eur. Arch. Psychiatry Clin. Neuroscience 244:50-52, 1995.
154. Blum, K., Sheridan, P.J., Wood, R. C., Braverman, E.R., Chen, T.J.H., Cull, J.G. and Comings, D.E.  The D2 dopamine receptor gene as a predictor of impulsive-addictive-compulsive behavior:  Bayes' theorem.  J. Royal Society of Medicine 89, 396-400, 1996.
155. Blum, K., Cull, J.G. and Comings, E.D.  Biogenetics of Reward Deficiency Syndrome.  American Scientist 84, 132-145, 1996.
156. Braverman, E.E. and Blum, K. Substance Use Disorder Exacerbates Brain Electrophysiological Abnormalities in a psychiatrically-ill population. Clinical EEG suppl. 27(4), 5-28, 1996
157. Wise, J.A., Morin, R.J., Sanderson, R. and Blum, K. Changes in plasma Carotenoid, Alpha-tocopherol and lipid peroxide levels in response to supplementation with concentrated fruit and vegetable extracts: a pilot study. Current Therapeutic Research 57)6), 446-462, 1996
158. Kaats, G.R., Blum, K., Fisher, J.A., Adelman, J.A. and Wood, R.  Effects of chromium picolinate supplementation on body composition: a randomized double blind placebo controlled study.  Current Therapeutic Research 57(10),747-756, 1996.
159. Blum, K. Braverman, E.R., Cull, J.G., Gill, J., Chen, T.H.J., Eisenberg, A., Sherman, M., Wood, R. and Comings, D.E. Polymorphism of the dopamine D2 receptor gene associates with brain electrophysiological abnormalities in humans: Exacerbation with Substance Use Disorder . Clinical EEG,;27(4 Suppl):5-27.  1996.
160. Braverman E., Blum K, Comorbid Psychiatric Disorders in a Holistic Health Clinic Society of Medicine, Vol 89, 1996.
161. Blum, K. , Braverman, ER, Wu, S., Cull, JG., Wood, R. et al. Association of polymorphisms of dopamine D2  receptor (DRD2 ), and dopamine transporter (DAT1) genes with schizoid/ avoidant behaviors (SAB). Molecular Psychiatry 2 : 239-246, 1997.
162. Blum, K. Cull, JG. Chen TJH, Garcia-Swan Susan, Holder,JM, Wood,R. Braverman, ER, Buci, LR., & Trachtenberg,MC. Clinical evidence For Effectiveness of PhencalTM in maintaining weight loss in an open-label, controlled, 2-year study. Current Therapeutic Research. 58 (10) 1997.
163. DeFrance, J.F., Hymel, C., Trachtenberg, M.C., Ginsberg, L.D., Schweitzer, F.C., Estes, S., Chen, T.J.H., Braverman, E.R., Cull, J.G. and Blum, K.  Enhancement of attention processing by Kantrol TM in healthy humans: A pilot study. Clinical EEG, 1997
164. Comings DE, Blum K. Reward deficiency syndrome: genetic aspects of behavioral disorders.Prog Brain Res.;126:325-41, 2000.
165. Blum, K. and E.R. Braverman  “Reward Deficiency Syndrome: A biogenetic Model for the treatment of impulsive, addictive and compulsive behaviors. Journal Psychoactive Drugs, 32: 1-12. 2001.
166. Blum, K. and Noble, EP.  First Conference on “Reward deficiency syndrome’: Genetic Antecedents and Clinical Pathways. Molecular Psychiatry vol. 6  supplement  Feb. 1 , 2001.
167. Blum,K. and Noble,EP Reward Deficiency Syndrome (RDS) : A biogenic model for the diagnosis and treatment of impulsive , addictive, and compulsive behaviors. Molecular Psychiatry 6: S2, 2001.
168. Blum, K. and Braverman, ER “Reward Deficiency Syndrome”: An emerging concept. Molecular Psychiatry,   6: S3, 2001.
169. Braverman, ER , Blum, K. Lubar, J, Lubar, Jo, Lubar, and Comings, DE. Genetic dopaminergic deficits: Clinical correlates to schizoid/avoidant personality, ADHD probands, pathological violence. P300 event related potential and TOVA attention test. Molecular psychiatry, 6: S5, 2001.
170. Holder, JM., Duncan, RC, Gissen, M., Miller,M., Braverman,ER and Blum, K. Increasing retention rates among the chemically dependent in residential treatment: auriculotherapy and subluxation-based chiropractic care. Molecular Psychiatry, 6 S8, 2001.
171. Braverman, E. and Blum, K., American Academy of Anti-Aging Medicine, 10th International Conference, December 2002. Poster Session: Adult Growth Hormone Deficiency: A Higher Compliance Delivery System.
172. Braverman ER, Blum K. P300 (latency) event-related potential: an accurate predictor of memory impairment. Clin Electroencephalogr. Jul; 34(3):124-39, 2003.
173. Braverman E, Blum K, Stanford M. “From Brain Science to Brain Based Medicine”, Medical Hypotheses; 63(5):919-20, 2004.
174. Chen, T.J.H, Blum, K, Payte, James, T., Schoolfield, J, Hopper, D., Stanford, M, Braverman, ER, “Narcotic Antagonists in Drug Dependence: Pilot Study Showing Enhancement of Compliance with Amino Acid and Enkephalinase Inhibition Therapy”, Medical Hypotheses, Feb. 25, 2004.
175. Chen J.H, T; Blum K, Mathews D, Fisher L, Schnautz N, Braverman ER, Schoolfield J, Downs BW, Comings DE. Are dopaminergic genes involved in a predisposition to pathological aggression? Hypothesizing the importance of “super normal controls” in psychiatric genetic research of complex behavioral disorders. Medical hypotheses, volume 65, Issue 4;703-707, 2005.
176. Braverman, E & Blum, K. “P300 (Latency) Event-Related Potential: An Accurate Predictor of Memory Impairment: Hormonal Correlates,” Accepted into Alzheimer’s Conference on Prevention of Dementia in Washington, DC; Published Alzheimer’s & Dementia, Vol 1, issue 1, Suppl 1, July 2005
177. Comings DE, Chen TJ, Blum K, Mengucci JF, Blum SH, Meshkin B. Neurogenetic interactions and aberrant behavioral co-morbidity of attention deficit hyperactivity disorder (ADHD): dispelling myths.Theor Biol Med Model. 23;2: 50, 2005.
178. Blum K, Chen TJ, Ross BD. Innate properties of H-Wave device, a small fiber stimulator provides the basis for a paradigm shift of electro-therapeutic treatment of pain with increased functional restoration associated with human neuropathies by affecting tissue circulation: a hypothesis.Med Hypotheses. 64(5):1066-7, 2005.
179. Braverman ER, Chen TJ, Schoolfield J, Martinez-Pons M, Arcuri V, Varshavskiy M, Gordon CA, Mengucci J, Blum SH, Meshkin B, Downs BW, Blum K. Delayed P300 latency correlates with abnormal Test of Variables of Attention (TOVA) in adults and predicts early cognitive decline in a clinical setting. Adv Ther. (4):582-600, 2006.
180. Blum K, Chen T, Meshkin B, Downs WB, Gorden C, Blum S, Braverman ER, Arcuri V. Varshavskiy M, Deutsch R, Martinez-Pons M. Reward Deficiency Syndrome in Obesity: A Preliminary Cross-Secontional Trail With a Genotrim Variant. Advances in Therapy. 23 (6) 1040-1051, 2006.
181. Blum K, Chen TJ, Martinez-Pons M, Dinubile NA, Waite RL, Schoolfield J, Blum SH, Mengucci J, Downs BW, Meshkin B. The H-Wave small muscle fiber stimulator, a nonpharmacologic alternative for the treatment of chronic soft-tissue injury and neuropathic pain: an extended population observational study.Adv Ther. 23(5):739-49, 2006.
182. Blum K, Chen TJH, Blum SH, Comings DE, Mengucci JF, Meshkin B, Downs BW, Braverman ER.  Reward Deficiency Syndrome (RDS): Neurogenetic Aspects of Aging and Related Behavioral Disorders Specific To Dopaminergic Pathways. Anti-Aging Therapeutics, 8: 9-26, 2006.
183. Blum K, Chen TJ, Meshkin B, Downs BW, Gordon CA, Blum S, Mengucci JF, Braverman ER, Arcuri V, Varshavskiy M, Deutsch R, Martinez-Pons M. Reward deficiency syndrome in obesity: a preliminary cross-sectional trial with a Genotrim variant. Adv Ther. 23(6):1040-51, 2006.
184. Blum K, DiNubile NA, Tekten T, Chen TJ, Waite RL, Schoolfield J, Martinez-Pons M, Callahan MF, Smith TL, Mengucci J, Blum SH, Meshkin B. H-Wave, a nonpharmacologic alternative for the treatment of patients with chronic soft tissue inflammation and neuropathic pain: a preliminary statistical outcome study. Adv Ther. 2006 May-Jun: 23(3):446-55.
185. Blum K, DiNubile NA, Tekten T, Chen TJ, Waite RL, Schoolfield J, Martinez-Pons M, Callahan MF, Smith TL, Mengucci J, Blum SH, Meshkin B. H-Wave, a nonpharmacologic alternative for the treatment of patients with chronic soft tissue inflammation and neuropathic pain: a preliminary statistical outcome study.Adv Ther. 23(3):446-55, 2006.
186. Blum K, Meshkin B, Downs BW. DNA based customized nutraceutical "gene therapy" utilizing a genoscore: a hypothesized paradigm shift of a novel approach to the diagnosis, stratification, prognosis and treatment of inflammatory processes in the human. Med Hypotheses. 66(5):1008-18, 2006.
187. Braverman ER, Chen T, Prihoda T, Sonntag W, Meshkin B, Downs W, Mengucci J, Blum S, Notaro A, Arcuri V, Varshavskiy M, Blum K. Plasma Growth Hormones, P300 Event-Related Potential and Test of Variables of Attention (T.O.V.A) Are Important Neuroendocrinological Predictors of Early Cognitive Decline in Clinical Setting: Evidence supported by structural Equation Modeling Parameter Estimates. Age 29(2-3):55-67, 2006.
188. Blum K, Chen, TJ, Meshkin B, Downs WB, Gordon, CA, Blum S, Mengucci JF, Braverman ER, Arcuri V, Deutch R, Martinez-Pons M. Genotrim a DNA-customized nutrigenomic product, targets genetic factors of obesity: Hypothesizing a dopamine-glucose correlation demonstrating reward deficiency syndrome (RDS). Medical Hypotheses, pages 68, 844-852, 2007.
189. Meshkin B, Blum K. Folate nutrigenetics: a convergence of dietary folate metabolism, folic acid supplementation, and folate antagonist pharmacogenetics.Drug Metab Lett. 1(1):55-60, 2007.
190. Blum K, Chen T, Meshkin B, Blum S, Mengucci J, Notaro A, Arcuri V, Waite R, Braverman ER. The PPAR-gamma Pro12Ala allele polymorphism of the Peroxisome Proliferator-Activated Receptor (gamma) Gene (PPARG2) Is a Risk Factor With a Self-Identified Obese Dutch Population. Gene Therapy & Molecular Biology.11:37-42, 2007
191. Chen T, Blum K, Waite R, Meshkin B, Schoolfield J, Downs WB, Braverman ER, Arcuri V, Varshavskiy M, Blum S, Mengucci, J Reuben C, Palomo T. Reward Deficiency Syndrome (RDS) and Substance Use Disorder (S.U.D.): The Gene Narcotic Attenuation Program (GNAP) including Haveos** (Synaptamine) Attenuates Addictive Related Behaviors. Advances in Therapy. 24(2): 402-14, 2007.
192. Braverman ER, Chen TJ, Prihoda TJ, Sonntag W, Meshkin B, Downs BW, Mengucci JF, Blum SH, Notaro A, Arcuri V, Varshavskiy M, Blum K. Plasma growth hormones, P300 event-related potential and test of variables of attention (TOVA) are important neuroendocrinological predictors of early cognitive decline in a clinical setting: evidence supported by structural equation modeling (SEM) parameter estimates. Age (Dordr). 29(2-3):55-67. doi: 10.1007/s11357-007-9030-3, 2007. 
193. Blum K, Chen TJ, Meshkin B, Waite RL, Downs BW, Blum SH, Mengucci JF, Arcuri V, Braverman ER, Palomo T. Manipulation of catechol-O-methyl-transferase (COMT) activity to influence the attenuation of substance seeking behavior, a subtype of Reward Deficiency Syndrome (RDS), is dependent upon gene polymorphisms: a hypothesis. Med Hypotheses. 69(5):1054-60, 2007.
194. Blum K, Chen TJ, Meshkin B, Downs BW, Gordon CA, Blum S, Mangucci JF, Braverman ER, Arcuri V, Deutsch R, Pons MM. Genotrim, a DNA-customized nutrigenomic product, targets genetic factors of obesity: hypothesizing a dopamine-glucose correlation demonstrating reward deficiency syndrome (RDS). Med Hypotheses. 68(4):844-52, 2007. 
195. Chen T, Blum K, Kaats G, Braverman ER, Eisenberg A, Sherman M, Davis K, Comings D, Wood R, Pullin D, Arcuri V, Varshavski M, Mengucci J, Blum S, Downs, B, Meskin B, Waite R, Williams L, Schoolfield J, Prihoda T, White L. “Cromium Picolinate (CrP) a putative anti-obesity nutrient induces changes in body composition as a function of the Taq1 dopamine D2 receptor polymorphisms in a randomized double-blind placebo controlled study.” Gene Therapy and Molecular Biology Vol 11, 161-170, 2007.
196. Blum K, Chen TJH, Meshkin B, Waite RL, Downs BW, Blum SH, Mengucci JF, Arcuri V, Braverman ER, Palomo T. Manipulation of Catechol-O Methyl Transferase (COMT) Activity to influence the attenuation of substance seeking behavior, a subtype of Reward Deficiency Syndrome (RDS), is dependent upon gene polymorphisms: A hypothesis. Med Hypotheses. 69(50: 1054-1060, 2007.
197. Blum K, Chen TJH, Downs BW, Meshkin B, Blum SH, Martinez Pons M, Mengucci JF, Waite RL, Arcuri V, Varshafski M, Braverman ER. Synaptamine (SG8839) An Amino-Acid Enkephalinase Inhibition Nutraceutical Improves Recovery of Alcoholics, A Subtype of Reward Deficiency Syndrome (RDS). Trends in Applied Sciences Research. 2(2): 132-138, 2007.
198. Chen TJH, Blum K, Mathews D, Fisher L, Schnautz N, Braverman ER, Schoolfield J, Downs BW, Blum SH, Mengucci J, Meskin B, Arcuri V, Bajaj A, Comings DE. Preliminary Association Of Both the Dopamine D2 Receptor (DRD2) [Taq1 A1 Allele] And The Dopamine Transporter (DAT1) [480 bp Allele] Genes With Pathological Aggressive Behavior, A Clinical Subtype Of Reward Deficiency Sybdrome (RDS) in Adolescents. Gene Ther  Mol  Biol. Volume 11, 93-112, 2007
199. Chen TJH, Blum K, Kaats G, Braverman ER, Pullin D, Downs BW, Martinez-Pons M, Blum SH, Mengucci J, Bagchi D, Bagchi M, Robarge A, Meskin B, Arcuri V, Varshavsky M, Notaro A, Comings DE, White L. Reviewing the role of putative candidate gebes in “Neurobesigenics”, a clinical subtype of Reward Deficiency Sundrome (RDS). Gene Ther Mol Biol. Volume 11, 61-74, 2007
200. Braverman ER, Chen TJH, Prihoda T, Sonntag W, Meshkin B, Downs BW, Mengucci J, Blum SH, Notero A, Arcuri V, Varshavski M, Blum K. Plasma growth hormones, P300 event-related potential and test of variables of attention (TOVA) are important neuroendocrinological predictors of early cognitive decline in a clinical setting: Evidence supported by structural equation modeling (SEM) parameter estimates. Springer, American Aging Association 2007.
201. Thomas JH Chen, Kenneth Blum, Daniel Mathews, Larry Fisher, Nancy Schnautz, Eric R. Braverman, John Schoolfield, Bernard W. Downs, Seth H. Blum, Julie Mengucci, Brian Meshkin, Vanessa Arcuri, Anish Bajaj, Roger L. Waite, David E. Comings. Preliminary association of both the Dopamine D2 Receptor (DRD2) [Taq1 A1 Allele] and the Dopamine Transporter (DAT1) [480 bp Allele] genes with pathological aggressive behavior, a clinical subtype of Reward Deficiency Syndrome (RDS) in adolescents. Gene Therapy & Mol. Biol. 11; 93-112. 2007
202. Blum K, THJ Chen, B W Downs, Waite RL, Meshkin B, Braverman R. Nutrigenomics : A Scientific Wonderland. Journal Of Social Sciences; Life Science issue (French Journal National Academy Sciences of France) 2007.
203. Thomas JH Chen, Kenneth Blum, Gilbert Kaats, Eric R. Braverman, Arthur Eisenberg, Mark Sherman, Katharine Davis, David E. Comings, Robert Wood, Dennis Pullin, Vanessa Arcuri, Michael Varshavski, Julie F. Mengucci, Seth H. Blum, Bernard W. Downs, Brian Meshkin, Roger L. Waite, Lonna Williams, John Schoolfield, Thomas J Prihoda, Lisa White. Chromium Picolinate (CrP) a putative anti-obesity nutrient induces changes in body composition as a function of the Taq1 dopamine D2 receptor polymorphisms in a randomized double-blind placebo controlled study.Gene Therapy & mol. Biol. 11: 161-170, 2007.
204. Blum K, Chen AL, Braverman ER, Comings DE, Chen TJ, Arcuri V, Blum SH, Downs BW, Waite RL, Notaro A, Lubar J, Williams L, Prihoda TJ, Palomo T, Oscar-Berman M. Attention-deficit-hyperactivity disorder and reward deficiency syndrome. Neuropsychiatr Dis Treat. 4(5):893-918, 2008.
205. Blum K, Chen AL, Chen TJ, Prihoda TJ, Schoolfield J, DiNubile N, Waite RL, Arcuri V, Kerner M, Braverman ER, Rhoades P, Tung H. The H-Wave device is an effective and safe non-pharmacological analgesic for chronic pain: a meta-analysis. Adv Ther. 25(7):644-57. doi: 10.1007/s12325-008-0073-3, 2008.
206. Oben JE, Ngondi JL, Blum K. Inhibition of Irvingia gabonensis seed extract (OB131) on adipogenesis as mediated via down regulation of the PPARgamma and leptin genes and up-regulation of the adiponectin gene. Lipids Health Dis.13;7: 44, 2008.
207. Blum K, Chen AL, Chen TJ, Braverman ER, Reinking J, Blum SH, Cassel K, Downs BW, Waite RL, Williams L, Prihoda TJ, Kerner MM, Palomo T, Comings DE, Tung H, Rhoades P, Oscar-Berman M. Activation instead of blocking mesolimbic dopaminergic reward circuitry is a preferred modality in the long term treatment of reward deficiency syndrome (RDS): a commentary. Theor Biol Med Model. 12;5:24, 2008.
208. Chen AL, Chen TJ, Braverman ER, Acuri V, Kemer M, Varshavskiy M, Braverman D, Downs WB, Blum SH, Cassel K, Blum K. Hypothesizing that marijuana smokers are at a significantly lower risk of carcinogenicity relative to tobacco-non-marijuana smokers: evidenced based on statistical reevaluation of current literature. J Psychoactive Drugs. 40(3):263-72, 2008.
209. Brian Meshkin, Thomas JH Chen, Amanda LC Chen, Thomas JH Prihoda, Hayley Morrisette4, Eric R. Braverman, Seth H. Blum, Kimberly Cassel, Lonna Williams, Roger L. Waite, B. Willliam Downs, Howard Tung, Patrick Rhoades, Kenneth Blum. Health economics of nutrigenomics in weight management Gene Therapy & Mol. Boil. 12: 25-30. 2008.
210. Blum K, Chen AL, Chen TJ, Rhoades P, Prihoda TJ, Downs BW, Waite RL, Williams L, Braverman ER, Braverman D, Arcuri V, Kerner M, Blum SH, Palomo T. LG839: anti-obesity effects and polymorphic gene correlates of reward deficiency syndrome.Adv Ther. 25(9):894-913, 2008.
211. Amanda LC Chen, Kenneth Blum, Thomas JH Chen, Jeffrey Reinking, Roger L Waite, Bernard W. Downs, Eric R. Braverman, Vanassa Arcuri, Mallory Kerner, Alison Notaro, Kimberly Cassel, Seth H. Blum, Debasis Bagchi, Manashi Bagchi, Ariel Robarge, Gilbert Kaats, David E. Comings, Patrick Rhoades, Lonna Williams, Howard Tung. The impact of biomics technology and DNA directed anti-obesity targeting of the brain reward circuitry. Gene Therapy & Mol Bio. 12: 45-68, 2008.
212. Blum K, Chen AL, Chen TJ, Prihoda TJ, Schoolfield J, DiNubile N, Waite RL, Arcuri V, Kerner M, Braverman ER, Rhoades P, Tung H. The H-Wave device is an effective and safe non-pharmacological analgesic for chronic pain: a meta-analysis. Adv Ther. 25(7):644-57, 2008.
213. Kenneth Blum, Thomas JH Chen, Amanda LC Chen, Patrick Rhoades, Thomas J Prihoda, B. William Downs, Debasis Bagchi, Manashi Bagchi, Seth H. Blum, Lonna Williams, Eric R. Braverman, Mallory Kerner, Roger L Waite, Brien Quirk, Lisa White, Jeffrey Reinking. Dopamine D2 Receptor Taq A1 allele predicts treatment compliance of LG839 in a subset analysis of pilot study in the Netherlands. Gene Therapy & Mol. Biol. 12: 129-140. 2008.
214. Blum K, Ho CK, Chen AL, Fulton M, Fulton B, Westcott WL, Reinl G, Braverman ER, Dinubile N, Chen TJ. The H-Wave((R)) Device Induces NO Dependent Augmented Microcirculation and Angiogenesis, Providing Both Analgesia and Tissue Healing in Sports Injuries. Phys Sportsmed. 36(1):103-14, 2008.
215. Blum K, Chen AL, Braverman ER, Comings DE, Chen TJ, Arcuri V, Blum SH, Downs BW, Waite RL, Notaro A, Lubar J, Williams L, Prihoda TJ, Palomo T, Oscar-Berman M. Attention-deficit-hyperactivity disorder and reward deficiency syndrome. Neuropsychiatr Dis Treat. 4(5):893-918, 2008.
216. Oben JE, Ngondi JL, Blum K. Inhibition of Irvingia gabonensis seed extract (OB131) on adipogenesis as mediated via down regulation of the PPARgamma and leptin genes and up-regulation of the adiponectin gene. Lipids Health Dis.13;7:44, 2008.
217. Blum K, Chen AL, Chen TJ, Braverman ER, Reinking J, Blum SH, Cassel K, Downs BW, Waite RL, Williams L, Prihoda TJ, Kerner MM, Palomo T, Comings DE, Tung H, Rhoades P, Oscar-Berman M. Activation instead of blocking mesolimbic dopaminergic reward circuitry is a preferred modality in the long term treatment of reward deficiency syndrome (RDS): a comentary. Theor Biol Med Model. 12;5: 24, 2008.
218. Chen AL, Chen TJ, Braverman ER, Acuri V, Kemer M, Varshavskiy M, Braverman D, Downs WB, Blum SH, Cassel K, Blum K. Hypothesizing that marijuana smokers are at a significantly lower risk of carcinogenicity relative to tobacco-non-marijuana smokers: evidenced based on statistical reevaluation of current literature. J Psychoactive Drugs. 40(3):263-72, 2008.
219. Kenneth Blum, Thomas JH Chen, Lonna Williams, Amanda LC Chen, William B. Downs, Roger L. Waite, T. Huntington, Simon Sims, Thomas Prihoda, Patrick Rhoads, Jeffrey Reinking, Dasha Braverman, Mallory Kerner, Seth H. Blum, Brien Quirk, Eric R Braverman. A short term pilot open label study to evaluate efficacy and safety of LG839, a customized DNA directed nutraceutical in obesity: Exploring Nutrigenomics. Gene Therapy & Mol. Boil. 12: 371-382. 2008
220. Blum K, Ho CK, Chen LC, Fulton M, Fulton B, Westcott WL, Reinl G, Braverman ER, DiNubile N, Chen TJH. The H-Wave Device Induces No-Dependent Augmented Microcirculation and Angiogenesis Providing Both Analgesia and Tissue Healing in Sports Injuries. The Physician and Sports Medicine. 36 (1): 103-115. 
221. Smith TL, Blum K, Callahan MF, Dinubile NA, Chen TJ, Waite RL H-Wave(R) induces arteriolar vasodilation in rat striated muscle via nitric oxide-mediated mechanisms. J Orthop Res. 27(9):1248-5, 2009.
222. Blum K, Chen TJ, Downs BW, Bowirrat A, Waite RL, Braverman ER, Madigan M, Oscar-Berman M, DiNubile N, Stice E, Giordano J, Morse S, Gold M. Neurogenetics of dopaminergic receptor supersensitivity in activation of brain reward circuitry and relapse: proposing "deprivation-amplification relapse therapy" (DART). Postgrad Med. 121(6):176-96. Review, 2009.
223. Chen AL, Chen TJ, Waite RL, Reinking J, Tung HL, Rhoades P, Downs BW, Braverman E, Braverman D, Kerner M, Blum SH, DiNubile N, Smith D, Oscar-Berman M, Prihoda TJ, Floyd JB, O'Brien D, Liu HH, Blum K. Hypothesizing that brain reward circuitry genes are genetic antecedents of pain sensitivity and critical diagnostic and pharmacogenomic treatment targets for chronic pain conditions. Med Hypotheses. Jan:72(1):14-22, 2009.
224. B. William Downs,  Amanda  LC Chen, Thomas JH Chen,  Roger L. Waite, Eric R. Braverman,  Mallory Kerner, Dasha  Braverman,  Patrick Rhoades, Thomas J Prihoda, Tomas Palomo,  Marlene Oscar –Berman, Jeffrey Reinking,  Seth H Blum , Nicholas A. DiNublie, Kenneth Blum. Nutrigenomic targeting of carbohydrate craving behavior: Can we manage obesity and aberrant craving behaviors with neurochemical pathway manipulation by Immunological Compatible Substances (nutrients) using a Genetic Positioning System (GPS) Map? Medical Hypotheses, 73(3):427-34. doi: 10.1016/j.mehy.2009.02.037, 2009.
225.   Braverman ER, Chen TJ, Chen AL, Arcuri V, Kerner MM, Bajaj A, Carbajal J, Braverman D, Downs BW,Blum K. Age-related increases in parathyroid hormone may be antecedent to both osteoporosis and dementia. BMC Endocr Disord. 13; 9:21. doi: 10.1186/1472-6823-9-21, 2009.
226. Fritch D, Blum K, Nonnemacher S, Haggerty BJ, Sullivan MP, Cone EJ. Identification and quantitation of amphetamines, cocaine, opiates, and phencyclidine in oral fluid by liquid chromatography-tandem mass spectrometry.J Anal Toxicol. 33(9):569-77, 2009.
227. Braverman ER, Chen TJ, Chen AL, Kerner MM, Tung H, Waite RL, Schoolfield J, Blum K. Preliminary investigation of plasma levels of sex hormones and human growth factor(s), and P300 latency as correlates to cognitive decline as a function of gender. BMC Res Notes. 7;2:126, 2009.
228. Downs BW, Chen AL, Chen TJ, Waite RL, Braverman ER, Kerner M, Braverman D, Rhoades P, Prihoda TJ, Palomo T, Oscar-Berman M, Reinking J, Blum SH, DiNubile NA, Liu HH, Blum K. Nutrigenomic targeting of carbohydrate craving behavior: can we manage obesity and aberrant craving behaviors with neurochemical pathway manipulation by Immunological Compatible Substances (nutrients) using a Genetic Positioning System (GPS) Map? Med Hypotheses. 73(3):427-34, 2009.
229. Eric R. Braverman, Amanda LC Chen, Thomas JH. Chen, John Schoolfield, Mallory Kerner, Roger L. Wait, Howard Tung, Kenneth Blum. Low Plasma Levels of Sex Hormones and Human Growth Factor(s) Correlate to Cognitive Decline as a Function of Gender. BMC-Research Notes. 2:126. doi:10.1186/1756-0500-2-126, 2009.
230. Kenneth Blum,  Amanda LH Chen, Thomas JH Chen, Roger L. Waite, B William Downs, Eric R. Braverman, Mallory Kerner, Howard Tung. Healing Enhancement of Chronic Venous Stasis Ulcers Utilizing H-Wave® Device Therapy: A Case Series. The Case Journal, 10; 3:54.  doi: 10.1186/1757-1626-3-54, 2010.
231. Braverman ER, Chen AL, Chen TJ, Schoolfield JD, Notaro A, Braverman D, Kerner M, Blum SH, Arcuri V, Varshavskiy M, Damle U, Downs BW, Waite RL, Oscar-Berman M, Giordano J, Blum K. Test of variables of attention (TOVA) as a predictor of early attention complaints, an antecedent to dementia .Neuropsychiatr Dis Treat. 15;6: 681-90. 2010.
232. Kenneth Blum,  Amanda LH Chen, Thomas JH Chen, Roger L. Waite, B William Downs, Eric R. Braverman, Mallory Kerner, Howard Tung. Healing Enhancement of Chronic Venous Stasis Ulcers Utilizing H-Wave® Device Therapy: A Case Series. The Case Journal, 10;3:54. doi: 10.1186/1757-1626-3-54, 2010.
233. Braverman ER, Chen AL, Chen TJ, Schoolfield JD, Notaro A, Braverman D, Kerner M, Blum SH, Arcuri V, Varshavskiy M, Damle U, Downs BW, Waite RL, Oscar-Berman M, Giordano J, Blum K. Test of variables of attention (TOVA) as a predictor of early attention complaints, an antecedent to dementia .Neuropsychiatr Dis Treat. 15;6: 681-90. 2010.
234. Chen AL, Chen TJ, Waite RL, Reinking J, Tung HL, Rhoades P, Downs BW, Braverman E, Braverman D, Kerner M, Blum SH, DiNubile N, Smith D, Oscar-Berman M, Prihoda TJ, Floyd JB, O'Brien D, Liu HH, Blum K. Hypothesizing that brain reward circuitry genes are genetic antecedents of pain sensitivity and critical diagnostic and pharmacogenomic treatment targets for chronic pain conditions. Med Hypotheses. 72(1):14-22. 2010.
235. Braverman ER, Bowirrat A, Damle UJ, Yeldandi S, Chen TJ, Madigan M, Kerner M, Huang SX, Savarimuthu S, Blum K. Adult growth hormone deficiency treatment with a combination of growth hormone and insulin-like growth factor-1 resulting in elevated sustainable insulin-like growth factor-1 and insulin-like growth factor binding protein 3 plasma levels: a case report. J Med Case Reports. 15; 4(1):305, 2010.
236. Miller DK, Bowirrat A, Manka M, Miller M, Stokes S, Manka D, Allen C, Gant C, Downs BW, Smolen A, Stevens E, Yeldandi S,Blum K. Acute intravenous synaptamine complex variant KB220™ "normalizes" neurological dysregulation in patients during protracted abstinence from alcohol and opiates as observed using quantitative electroencephalographic and genetic analysis for reward polymorphisms: part 1, pilot study with 2 case reports. Postgrad Med. 2010 Nov; 122(6):188-213. doi: 10.3810/pgm. 11.2236, 2010.
237. Blum K, Chen TJ, Morse S, Giordano J, Chen AL, Thompson J, Allen C, Smolen A, Lubar J, Stice E, Downs BW, Waite RL, Madigan MA, Kerner M, Fornari F, Braverman ER. Overcoming qEEG abnormalities and reward gene deficits during protracted abstinence in male psychostimulant and polydrug abusers utilizing putative dopamine D₂ agonist therapy: part 2. Postgrad Med. 122(6):214-26. doi: 10.3810/pgm.2010.11.2237, 2010.
238. Blum K, Giordano J, Morse S, Liu Y, Tan J, Bowirrat A, Smolen A, Waite R, Downs W, Madigan M, Kerner M,  Fornari F, Stice E, Braverman, E, Miller D. Bailey J. Genetic Addiction Risk Score (GARS) Analysis: Exploratory development of polymorphic risk alleles in poly-drug addicted males.  International J.  Omics and Biotechnology, DOI:http://www.doaj.org/doaj, 2010.
239. Bowirrat A, Chen TJ, Blum K, Madigan M, Bailey JA, Chuan Chen AL, Downs BW, Braverman ER, Radi S, Waite RL, Kerner M, Giordano J, Morse S, Oscar-Berman M, Gold M. Neuro-psychopharmacogenetics and Neurological Antecedents of Posttraumatic Stress Disorder: Unlocking the Mysteries of Resilience and Vulnerability. Curr Neuropharmacol. 8(4):335-58. doi: 10.2174/157015910793358123, 2010.
240. Braverman ER, Chen AL, Chen TJ, Schoolfield JD, Notaro A, Braverman D, Kerner M, Blum SH, Arcuri V, Varshavskiy M, Damle U, Downs BW, Waite RL, Oscar-Berman M, Giordano J, Blum K. Test of variables of attention (TOVA) as a predictor of early attention complaints, an antecedent to dementia. Neuropsychiatr Dis Treat. 15;6: 681-90, 2010.
241. Blum K, Chen AL, Chen TJ, Downs BW, Braverman ER, Kerner M, Savarimuthu S, Bajaj A, Madigan M, Blum SH, Reinl G, Giordano J, Dinubile N. Healing enhancement of chronic venous stasis ulcers utilizing H-WAVE(R) device therapy: a case series. Cases J. 10; 3:54, 2010.
242. Blum K, Giordano J, Morse S, Bowirrat A, Madigan M, Downs W, Waite R, Kerner M,  Damle U, Braverman ER, Bauer G, Femino J, Bailey J, Dinunile N, Miller D, Archer T, Simpatico T. Understanding the high mind  Humans are still evolving genetically. IIOAB-India 1(2)1-14, 2010.
243. Stice E, Yokum S, Blum K, Bohon C. Weight gain is associated with reduced striatal response to palatable food. J Neurosci. 30(39):13105-9., 2010.
244. Blum K, Chen TJ, Chen AL, Madigan M, Downs BW, Waite RL, Braverman ER, Kerner M, Bowirrat A, Giordano J, Henshaw H, Gold MS. Do dopaminergic gene polymorphisms affect mesolimbic reward activation of music listening response? Therapeutic impact on Reward Deficiency Syndrome (RDS).Med Hypotheses. 74(3):513-20, 2010.
245. Smith TL, Callahan MF, Blum K, Dinubile NA, Chen TJ, Waite RL.(2011) H-Wave® effects on blood flow and angiogenesis in longitudinal studies in rats. J Surg Orthop Adv. 2011 Winter; 20(4):255-9.
246. Blum K, Chen AL, Oscar-Berman M, Chen TJ, Lubar J, White N, Lubar J, Bowirrat A, Braverman E,Schoolfield J, Waite RL, Downs BW, Madigan M, Comings DE, Davis C, Kerner MM, Knopf J, Palomo T,Giordano JJ, Morse SA, Fornari F, Barh D, Femino J, Bailey JA. Generational association studies of dopaminergic genes in reward deficiency syndrome (RDS) subjects: selecting appropriate phenotypes for reward dependence behaviors. Int J Environ Res Public Health.  8(12):4425-59. doi: 10.3390/ijerph8124425, 2011.
247. Kenneth Blum, Amanda LC Chen, Thomas JH Chen, Roger L. Waite, Nicholas DiNubile, B. William Downs, Mallory Kerner, Eric Braverman, Thomas J Prihoda, Howard Tung. Chronic H-Wave® Device Stimulation and Program Induces Significant Increases in the Range of Motion of Post- Operative Rotator Cuff Reconstruction in a Double-Blinded Randomized Placebo Controlled Human Study. BMC Musculoskeletal Disorders. 10:132. doi:10.1186/1471-2474-10-132
248. Westcott WL, Chen T, Neric FB, DiNubile N, Bowirrat A, Madigan M, Downs BW, Giordano J, Morse S, LC Chen A, Bajaj A, Kerner M, Braverman E, Reinl G, Blakemore M, Whitehead S, Sacks L, Blum K. The Marc ProTM Device Improves Muscle Performance and Recovery from Concentric and Eccentric Exercise Induced Muscle Fatigue in Humans: A Pilot Study. JEPonline 14(2):55-67, 2011.
249. Blum K, Han D, Hauser M, Downs BW, Giordano J, Borten J, Winchell W, Simpatico T, Barh D. Nrueogenetic impairments  of brain reward circuitry links to Reward Deficiency Syndrome(RDS) as evidenced by genetic addiction risk score(GARS): A case study. IIOAB 4(1): 4-9.
250. Chen TJ, Blum K, Chen AL, Bowirrat A, Downs WB, Madigan MA, Waite RL, Bailey JA, Kerner M, Yeldandi S, Majmundar N, Giordano J, Morse S, Miller D, Fornari F, Braverman ER. Neurogenetics and clinical evidence for the putative activation of the brain reward circuitry by a neuroadaptagen: proposing an addiction candidate gene panel map. J Psychoactive Drugs. 43(2):108-27, 2011.
251. Blum K, Giordano j, Morse S, Liu Y, Tain J, Bowirrat A, Smolen A, Waite R, Down B, Madigan M, Kerner M, Fornari F, Barverman E, Miller D, Bailey J. Addiction Risk Score (Gars) Analysis: Exploratory Development of Polymorphic risk Alleles in Polydrug addicted males.  IIOAB Vol1(20), 1-14.
252. Kenneth Blum, John Giordano, Siobhan Morse, Arthur Anderson, Javier Carbajal, Roger Waite, Bernarld Downs, Jaclyn Downs, Margaret Madigan, Debmalya Barh, Eric Braverman. Hypothesizing Synergy between Acupuncture/ Auriculotherapy and Natural Activation of Mesolimbic Dopaminergic Pathways: Putative Natural Treatment Modalities for the Reduction of Drug Hunger and Relapse  IIOAB Letters Vol 1, No 1, 2011.
253. Westcott WL, Chen T, Neric FB, DiNubile N, Bowirrat A, Madigan M, Downs BW, Giordano J, Morse S, LC Chen A, Bajaj A, Kerner M, Braverman E, Reinl G, Blakemore M, Whitehead S, Sacks L, Blum K. The Marc ProTM Device Improves Muscle Performance and Recovery from Concentric and Eccentric Exercise Induced Muscle Fatigue in Humans: A Pilot Study. JEPonline 14(2):55-67, 2011.
254. Blum K, Chen TJ, Bailey J, Bowirrat A, Femino J, Chen AL, Simpatico T, Morse S, Giordano J, Damle U,Kerner M, Braverman ER, Fornari F, Downs BW, Rector C, Barh D, Oscar-Berman M. Can the chronic administration of the combination of buprenorphine and naloxone block dopaminergic activity causing anti-reward and relapse potential? Mol Neurobiol. 44(3):250-68. doi: 10.1007/s12035-011-8206-0, 2011.
255. Blum K, Fornari F, Downs BW, Waite RL, Giordano J, Smolen A, Lui Y, Tain J, Majmundr N, Braverman ER. Chapter 19: Genetic Addiction Risk Score (GARS): Testing for Polygentic Predisposition and Risk for Reward Deficiency Syndrome (RDS).  in Gene Therapy Applications (Ed. C King) pages 327-362.
256. DiNubile N, Westcott W, Reinl G, Bajaj A, Braverman ER, Madigan MA, Giordano J, Blum K. The MarcProTM Device is  a Novel Paradigm Shift in Muscle Conditioning, Recovery and Performance: Induction of Nitric Oxide (NO) Dependent Enhanced Microcirculation Coupled with Angiogenesis Mechanisms. JEPonline,14(5):10-19, 2011.
257. Westcott W, Varghesse J, Dinubile N, Moynih N, Loud RL, Whitehead S, Brothers S, Giordano J, Morse S, Madigan M, Blum K. Exercise and Nutrition More Effective than Exercise Alone for Increasing Lean Weight and Reducing Resting Blood Pressure. Exercise and Nutrition More Effective than Exercise Alone for Increasing Lean Weight and Reducing Resting Blood Pressure. JEPonline. 14 (3), 2011.
258. Blum K, Bowirrat A, Downs BW, Waite RL, Giordano J, Morse S, Madigan M, Downs JM, Braverman ER, Polanin M, Fornari F,  Simpatico T. Nutrigenomics of Neuradaptogen Amino-Acid-Therapy (NAAT)™: Overcoming  Carbohydrate Bingeing and Overeating Through Neurometabolic Mechanisms Journal of Functional Food in Health and Chronic Disease. (9):310-378, 2011.
259. Blum K, Bailey J, Gonzalez AM, Oscar-Berman M, Liu Y, Giordano J, Braverman E, Gold M. (2011) Neuro-Genetics of Reward Deficiency Syndrome (RDS) as the Root Cause of "Addiction Transfer": A New Phenomenon Common after Bariatric Surgery. J Genet Syndr Gene Ther. 23;2012(1). pii: S2-001.
260. Blum K, Chen ALCH, Chen TJH, Lubar J, White N, Lubar J, Bowirrat A, Braverman ER, Scholfield J, Waite RL, Downs BW, Madigan M, Comings DE, Davis C Kerner M, Palomo T, Stice E , Oscar-Berman M, Giordano J, Morse S, Bailey J. Generational association studies of dopaminergic genes in reward deficiency syndrome (RDS) subjects: selecting appropriate phenotypes for reward dependence behaviors. International Journal of environmental Research and Public Health. 8(2) 4425-4459, 2011.
261. Archer T, Oscar-Berman M, Blum K. Epigenetics in Developmental Disorder: ADHD and EndophenotypesJ Genet Syndr Gene Ther.  2(104). pii: 1000104, 2011.
262. Braverman ER, Braverman D, Acuri V, Kerner K, Downs BW and Blum K. Sustainable weight loss and muscle gain utilizing the Rainbow Diet, Diethypropion (Tenuate) [A noradrenergic Agonist], Synaptamine Complex{Kb220} {a dopaminergic agonist], hormonal deficiency repletion therapy and exercise. The Bariatrician: American journal of bariatric medicine, 2011.
263. Blum K, Liu Y, Shriner R, Gold MS. Reward circuitry dopaminergic activation regulates food and drug craving behavior. Curr Pharm Des. 17(12):1158-67, 2011.
264. Blum K, Gold MS. Neuro-chemical activation of brain reward meso-limbic circuitry is associated with relapse prevention and drug hunger: a hypothesis. Med Hypotheses. 76(4):576-84, 2011.
265. Blum K, Chen AL, Oscar-Berman M, Chen TJ, Lubar J, White N, Lubar J, Bowirrat A, Braverman E, Schoolfield J, Waite RL, Downs BW, Madigan M, Comings DE, Davis C, Kerner MM, Knopf J, Palomo T, Giordano JJ, Morse SA, Fornari F, Barh D, Femino J, Bailey JA. Generational association studies of dopaminergic genes in reward deficiency syndrome (RDS) subjects: selecting appropriate phenotypes for reward dependence behaviors. Int J Environ Res Public Health. 8(12):4425-59, 2011. 
266. Blum K, Oscar-Berman M, Giordano J, Downs B, Simpatico T, Han D, Femino J. Neurogenetic Impairments of Brain Reward Circuitry Links to Reward Deficiency Syndrome (RDS): Potential Nutrigenomic Induced Dopaminergic Activation. J Genet Syndr Gene Ther. 2012 Oct 17;3(4). doi:pii: 1000e115.
267. Archer T, Oscar-Berman M, Blum K, Gold M. Neurogenetics and Epigenetics in Impulsive Behaviour: Impact on Reward Circuitry. J Genet Syndr Gene Ther. 3(3):1000115, 2012.
268. Blum K, Chen AL, Giordano J, Borsten J, Chen TJ, Hauser M, Simpatico T, Femino J, Braverman ER, Barh D. The addictive brain: all roads lead to dopamine. J Psychoactive Drugs. 44(2):134-43, 2012.
269. Blum K, Werner T, Carnes S, Carnes P, Bowirrat A, Giordano J, Oscar-Berman M, Gold M. Sex, drugs, and rock 'n' roll: hypothesizing common mesolimbic activation as a function of reward gene polymorphisms. J Psychoactive Drugs. 44(1):38-55, 2012.
270. Miller M, Chen A, Stokes S, et al., Early intervention of intravenous KB220IV_neuroadaptagen amino-acid therapy (NAAT)TM improves behavioral outcomes in a residential addiction treatment program: a pilot study. Journal of Psychoactive Drugs, 44:398-409, 2012.
271. Correlation of the Taq1 Dopamine D2 Receptor Gene and Percent Body Fat in Obese and Screened Control Subjects: A Preliminary Report. Chen Alc, Blum K, Chen TJH, Giordano J, Downs BW, Han D., Barh D., Braverman. Journal of Food & Function (J Royal Society of Chemistry). 3(1): 40-48, 2012
272. Blum K, Oscar-Berman M, Stuller E, et al., Neurogenetics and nutrigenomics of neuro-nutrient therapy for Reward Deficiency Syndrome (RDS): clinical ramifications as a function of molecular neurobiological mechanisms. Journal of Addiction Research & Therapy, 3:1-44, 2012.
273. Blum K, Bailey J, Giordano J, Borsten J, Waite RL, Downs BW, Downs JM, Madigan M, Fornarii F., Simpatico T, Jones D, Braverman, Barh D. Diagnosis and Healing in Veterans Suspected of Suffering From Post-traumatic Stress Disorder (PTSD) Using Reward Gene Testing and Reward Circuitry Natural Dopaminergic Activation. Omics Genetic Syndromes & Gene Therapy 3 (3) 100116,2012.
274. Morse S, Giordano J, Perrine K, Downs BW, Waite RL, Madigan M, Bailey J, Braverman, Damle U, Simpatico T, Moelelr MD, Blum K. Audio Therapy Significantly Attenuates Aberrant Mood in Residential Patient Addiction Treatment: Putative Activation of Dopaminergic Pathways in the Meso-Limbic Reward Circuitry of Humans. Journal of Addiction Research & Therapy S3:001. doi:10.4172/2155-6105.S3- 001
275. Neuropsychiatric Genetics of Happiness, Friendships and Politics: Hypothesizing that “Birds of a Feather (Homophily)” Flock Together as a Function of “Reward Gene (s)” Polymorphisms.Blum K, Oscar-Berman M, Bowirrat A, Giordano J, Madigan M, Braverman ER, Fornari F.  Journal Genetic Syndromes & Gene Therapy 3(2) in press 2012
276. Neuropsychiatric Genetics of Happiness, Friendships and Politics: A new era in understanding social interface. Blum, K, Oscar-Berman-M, Giordano J, Simpatico T, Lohman R, Hauser M, Borsten J, Braverman ER. Genetic Syndromes & Gene Therapy 3(2) 1000e106, 2012.
277. Blum K, Giordano J, Oscar-Berman M, Bowirrat A, Simpatico T, Barh D. Diagnosis and Healing In Veterans Suspected of Suffering from Post-Traumatic Stress Disorder (PTSD) Using Reward Gene Testing and Reward Circuitry Natural Dopaminergic Activation. J Genet Syndr Gene Ther. 3(3):1000116, 2012.
278. Bowirrat A, Amanda LCH, Madigan M, Chen TJH, Bailey J, Braverman ER, Kerner M, Giordano J , Morse S, Downs BW, Waite RL, Oscar –Berman M, Blum K. Neuropsychopharmacology and Neurogenetic Aspects of Executive Functioning: Are Humans “Hard Wired” To Achieve Appropriate Goals?  Molecular Neurobiology, 45(2):298-313, 2012.
279. Blum K Oscar-Berman, Femino J, Waite RL, Benya L, Giordano J, B.W. Downs, Braverman Er, Loehmann R, Dushaj K, Simpatico T, Hauser M, Barh D, McLaughlin (2013) Withdrawal from Buprenorphine/naloxone and Maintenance with a  Natural Dopaminergic Agonist: a Cautionary Note. J Addict Res Ther. 4: 146. Dol: 10.4172/2155-6105.1000146.
280. Blum K, Werner T, Carnes S, et al., Drugs and Rock ‘N’ Roll: Hypothesizing Common mesolimbic activation as a function of reward gene polymorphisms. Journal of Psychoactive Drugs, 44:38-55, 2012.
281. Blum K, Gardner E, Oscar-Berman M, Gold M. “Liking” and “Wanting” Linked to Reward Deficiency Syndrome (RDS): Hypothesizing differential resposivity in brain reward circuitry Cur Pharm Des. 18(1):113-8, 2012.
282. Blum K, Bagchi D, Barh D, Giordano J, Morse S, Downs BW, Waite RL, Downs JM, Madigan M , Ross –Coker C, Archer T, Braverman ER. Sugar craving a world epidemic: Is there a nutrigenomic solution?  Journal of Functional Foods. 1(9) 310-378, 2012.
283. Archer T, Oscar-Berman-M, Blum K, Gold M. Neurogenetics and Epigenetics in Impulsive Behavior Impact in Reward Circuitry.  Genetic Syndromes & Gene Therapy 3(3) 1000115, 2012.
284. Blum K, Giordano J, Borsten J, Downs BW, Hauser M, Simpatico T,Lohman R, Braverman ER, Barh D. Translational research to uncover diagnostic & therapeutic gene targets emerging in a genomic era: From bench to bedside.  Journal of Genetic Disorders & Disease Information. 1(1) 100e103 .2012.
285. Blum K, Chen AL, Giordano J, Borsten J, Chen TJ, Hauser M, Simpatico T, Femino J, Braverman ER, Barh D. The addictive brain: all roads lead to dopamine. J Psychoactive Drugs. 44(2):134-43, 2012.
286. Miller M, Chen ALC, Stokes S, Silverman S, Bowirrat A, Manka M, Manka D, Miller D,  Perrine K,  Chen TJH, Bailey J,  Downs BW, Waite RL, Madigan M, Braverman ER, Damle U, Kerner M, Giordano J, Morse S, Oscar-Berman M, Barh D, Blum K. Early intravenous KB220V-Neuroadaptagen Amino-Acid Therapy (NAAT) improves behavioral outcomes in a residential addiction treatment program: A pilot study. Journal Psychoactive Drugs, 44(5):398-409, 2012.
287. Blum K, Oscar-Berman M, Stuller E, Miller D, Giordano J, Morse S, McCormick L, Downs BW, Wait RL, Barh D, Neal D, Braverman ER, Lohmann R, Borsten J, Hauser M, Han D, Liu Y, Simpatico T. Neurogentics and Nutrigenomics of Neuro-Nutrient Therapy for Reward Deficiency Syndrome (RDS): Clinical Ramifications as a function of Molecular Neurobiological Mechanisms. Omics Journal of Addiction Research & Therapy  3:139. doi:10.4172/2155-6105.1000139.
288. Blum K, Oscar-Berman, M, Giordano J, Downs BW, Simpatico T, Han D, Femino J. Neurogenetic impairments of brain reward circuitry links to Reward Deficiency syndrome (RDS): Potential Nutrigenomic Induced Dopaminergic Activation. Omics Journal of Genetic Syndromes & Gene Therapy, 3(4), 2012. 
289. Blum K, Oscar-Berman M, Bowirrat A, Giordano J, Madigan M, Braverman ER, Barh D, Hauser M, Borsten J, Simpatico T.  Neuropsychiatric Genetics of Happiness, Friendships, and Politics: Hypothesizing Homophily ("Birds of a Feather Flock Together") as a Function of Reward Gene Polymorphisms.J Genet Syndr Gene Ther. 13;3(112), 2012.
290. Blum K (with J.Giordano, J Borsten, M Hauser, BW Downs, M Madigan, T. Simpatico, J Femino and ER Braverman . The Addiction Gene: Why millions are inherently at risk ? Colliers April 2012.
291. Braverman E, Oscar-Berman M, Lohmann R, Kennedy R, Kerner M, Dushaj K, Blum K. Low and Normal IGF-1 Levels in Patients with Chronic Medical Disorders (CMD) is Independent of Anterior Pituitary Hormone Deficiencies: Implications for Treating IGF-1 Abnormal Deficiencies with CMD. J Genet Syndr Gene Ther.; 4(123). doi:pii: 1000123, 2013.
292. Archer T, Oscar-Berman M, Blum K, Gold M. Epigenetic Modulation of Mood Disorders. J Genet Syndr Gene Ther. 4(120), 2013.
293. Blum K, Oscar-Berman M, Barh D, Giordano J, Gold M. Dopamine Genetics and Function in Food and Substance Abuse. J Genet Syndr Gene Ther. 4(121), 2013.
294. Campbell H, Oscar-Berman M, Giordano J, Beley T, Barh D, Downs B, Blum K. Common Phenotype in Patients with Both Food and Substance Dependence: Case Reports. J Genet Syndr Gene Ther. 6;4(122), 2013. 
295. Braverman ER, Blum K, Damle UJ, Kerner M, Dushaj K, Oscar-Berman M. Evoked Potentials and Neuropsychological Tests Validate Positron Emission Topography (PET) Brain Metabolism in Cognitively Impaired Patients. PLoS One. 8(3):e55398. doi: 10.1371/journal.pone.0055398, 2013.
296. Barh D, Barve N, Gupta K, Chandra S, Jain N, Tiwari S, Leon-Sicairos N, Canizalez-Roman A, dos Santos AR, Hassan SS, Almeida S, Ramos RT, de Abreu VA, Carneiro AR, Soares Sde C, Castro TL, Miyoshi A, Silva A, Kumar A, Misra AN, Blum K, Braverman ER, Azevedo V. Exoproteome and secretome derived broad spectrum novel drug and vaccine candidates in Vibrio cholerae targeted by Piper betel derived compounds. PLoS One. 8(1):e52773. doi: 10.1371/journal.pone.0052773, 2013.
297. Hill, E, Han D, Dumouchel P, et al., Long Term SuboxoneTM Emotional Reactivity As Measured by Automatic Detection in Speech. PLOS ONE, 8:1-14, 2013. 
298. Blum K, Femino J, Teitlebaum S, Giordano J,  Oscar-Berman M. Molecular Neurobiology of Addiction recovery : 12 step program & Fellowship. SpringerNeuroscienceBrief, 2013.
299. Yarnell S, Oscar-Berman M, Avena N, Blum K, Gold M. Pharmacotherapies for Overeating and Obesity. J Genet Syndr Gene Ther. 4(3):131, 2013.
300. Braverman E, Oscar-Berman M, Lohmann R, Kennedy R, Kerner M, Dushaj K, Blum K. Low and Normal IGF-1 Levels in Patients with Chronic Medical Disorders (CMD) is Independent of Anterior Pituitary Hormone Deficiencies: Implications for Treating IGF-1 Abnormal Deficiencies with CMD.J Genet Syndr Gene Ther. 4(123). doi:pii: 1000123, 2013.
301. Archer T, Oscar-Berman M, Blum K, Gold M. Epigenetic Modulation of Mood Disorders. J Genet Syndr Gene Ther. 4(120). doi:pii: 1000120, 2013.
302. Blum K, Oscar-Berman M, Barh D, Giordano J, Gold M. Dopamine Genetics and Function in Food and Substance Abuse. J Genet Syndr Gene Ther. 10;4(121). doi:pii: 1000121, 2013.
303. Braverman ER, Blum K, Damle UJ, Kerner M, Dushaj K, Oscar-Berman M. Evoked potentials and neuropsychological tests validate Positron Emission Topography (PET) brain metabolism in cognitively impaired patients. PLoS One. 8(3):e55398. doi: 10.1371/journal.pone.0055398, 2013. 
304. Barh D, Barve N, Gupta K, Chandra S, Jain N, Tiwari S, Leon-Sicairos N, Canizalez-Roman A, dos Santos AR, Hassan SS, Almeida S, Ramos RT, de Abreu VA, Carneiro AR, Soares Sde C, Castro TL, Miyoshi A, Silva A, Kumar A, Misra AN, Blum K, Braverman ER, Azevedo V. Exoproteome and secretome derived broad spectrum novel drug and vaccine candidates in Vibrio cholerae targeted by Piper betel derived compounds. PLoS One. 8(1):e52773. doi: 10.1371/journal.pone.0052773, 2013. 
305. Barh D, Gupta K, Jain N, Khatri G, León-Sicairos N, Canizalez-Roman A, Tiwari S, Verma A, Rahangdale S, Shah Hassan S, dos Santos AR, Ali A, Guimarães LC, Thiago Jucá Ramos R, Devarapalli P, Barve N, Bakhtiar M, Kumavath R, Ghosh P, Miyoshi A, Silva A, Kumar A, Misra AN, Blum K, Baumbach J, Azevedo V. Conserved host-pathogen PPIs. Globally conserved inter-species bacterial PPIs based conserved host-pathogen interactome derived novel target in C. pseudotuberculosis, C. diphtheriae, M. tuberculosis, C. ulcerans, Y. pestis, and E. coli targeted by Piper betel compounds. Integr Biol (Camb). 5(3):495-509. doi: 10.1039/c2ib20206a, 2013.
306. Downs B, Oscar-Berman M, Waite R, et al., Have we hatched the addiction egg: reward efficiency syndrome solution system. Journal of Genetic Syndromes & Gene Therapy, 4:1-9, 2013.
307. Blum K, Oscar-Berman M, Gardner E, Simpatico T, Gold MS. Neurogenetics and Neurobiology of  Dopamine in Anhedonia. Chapter in Anhedonia Book, (ed M.Ristner)  Frontiers of Neuroscience , 2013.
308. Blum K, Olive MF, Wang KW, Macelo F, Borsten J, Giordano J, Hauser M, Gold MS. Hypothesizing that designer drugs containing Cathinones (“Bath Salts”) have profound neuro-inflammatory effects and dangerous neurotoxic response following human consumption. Med Hyp  Med Hypotheses. doi:pii: S0306-9877(13)00285-5. 10.1016/j.mehy.2013.06.007, 2013.
309. Barh D, Gupta K, Jain N, Khatri G, León-Sicairos N, Canizalez-Roman A, Tiwari S, Verma A, Rahangdale S, Shah Hassan S, dos Santos AR, Ali A, Guimarães LC, Thiago Jucá Ramos R, Devarapalli P, Barve N, Bakhtiar M, Kumavath R, Ghosh P, Miyoshi A, Silva A, Kumar A, Misra AN, Blum K, Baumbach J, Azevedo V. Conserved host-pathogen PPIs. Globally conserved inter-species bacterial PPIs based conserved host-pathogen interactome derived novel target in C. pseudotuberculosis, C. diphtheriae, M. tuberculosis, C. ulcerans, Y. pestis, and E. coli targeted by Piper betel compounds. Integr Biol (Camb). Mar;5(3):495-509, 2013.
310. Kushner S, Han D, Oscar-Berman, et al., Declinol a complex containing Kudzu, Bitter Herbs (Gentian, Tangerine Peel) and Bupleurum, significantly reduced Alcohol Use Disorder (AUD) Scores in moderate to heavy drinkers: a pilot study. Journal of Addiction Research & Therapy, 4:1-18, 2013.
311. Blum K, Thompson B, Oscar-Berman M, et al., Genospirituality: Our Beliefs, Our Genomes, and Addictions. Journal of Addiction Research & Therapy, 5:1-18, 2013.
312. Blum K, Oscar-Berman M, DiNubile N, et al., Coupling genetic addiction risk scores (GARS) with electrotherapy: fighting iatrogenic opioid dependence. Journal of Addiction Research & Therapy, 4:1-8, 2013.
313. Blum K, Han D, Hauser M, Downs B, Giordano J, Borsten J, Winchell E, Simpatico T, Madigan M, Barh D, Neurogenetic impairments of brain reward circuity links to reward deficiency syndrome (RDS) as evidenced by genetic addiction risk score (GARS): A case study. The Institute of Integrative Omics & Applied Biotechnoogy Journal, 4:4-9, 2013.
314. Ashton J, Blum K, Everything you need to know about global alcohol policy. Addiction Research & Therapy, 5: 1-2, 2014.
315. Berkinbayev S, Rysuly M, Mussayev A, Blum K, et al., Apolipoprotein gene polymorphisms (APOB, APOC111, APOE) in the development of coronary heart disease in ethnic groups of Kazakhstan. 5:1-22 2014.
316. Blum K, Oscar-Berman M, Badgaiyan R, Palomo T, Gold M, Hypothesizing dopaminergic genetic antecedents in schizophrenia and substance seeking behavior. Medical Hypotheses, 82:606-614, 2014.
317. Blum K, Schoenthaler S, Oscar-Berman M, Giordano J, Madigan M, Braverman E, Jones S, Han D, Drug abuse relapse rates linked to level of education: can we repair hypodopaminergic-induced cognitive decline with nutrient therapy? The Physician and Sports Medicine, 42:1-16, 2014.
318. Blum K, Oscar-Berman M, Blum S, Madigan M, Walte R, McLaughlin T, Barh D, Can genetic testing coupled with enhanced dopaminergic activation reduce recidivism rates in the workers compensation legacy cases? Alcoholism and Drug Dependence, 2:1-3, 2014.
319. Blum K, Oscar-Berman M, Badgaiyan R, et al., Dopaminergic neurogenetics of sleep disorders in Reward Deficiency Syndrome (RDS). Sleep Disorders & Therapy, 3:1-3, 2014.
320. Blum K, Oscar-Berman M, Downs W, et al., Hypothesizing that putative dopaminergic, melatonin, benzodiazepine reward circuitry receptor(s) activator provides sleep induction benefits. Sleep Disorders & Therapy, 3:1-10, 2014.
321. Blum K, Oscar-German M, Waite R, A multi-locus approach to treating fibromyalgia by boosting dopaminergic activity in the meso-limbic system of the brain. Journal of Genetic Syndromes & Gene Therapy, 5: 1-5, 2014.
322. Blum K, Oscar-Berman M, Badjaiyan R, et al., Hypothesizing darkness induced alcohol intake linked to dopaminergic regulation of brain function. Psychology (Irvine), 5:282-288, 2014.
323. Blum K, Oscar-Berman M, Braverman E, et al., Raising endogenous brain levels of kynurenic acid may produce anti-reward and enhance suicide ideation. Journal of Alcoholism & Drug Dependence, 2:1-1, 2014.
324. Gold M, Blum K, Oscar-Berman M, et al., Low dopamine function in attention deficit/hyperactivity disorder: should genotyping signify early diagnosis in children? 126:153-177, 2014.
325. Vital M, Napolitano C, Oscar-Berman M, et al., Neurophysiological measures and alcohol use disorder (AUD): hypothesizing links between clinical severity index and molecular neurobiological patterns. Addiction Research & Therapy, 5: 1-7, 2014.
326. Waite R, Oscar-Berman M, Braverman E, et al., Quantitative Electroencephalography Analysis (qEEG) of Neuro-Electro-Adaptive Therapy 12™ [NEAT12] Up-Regulates Cortical Potentials in an Alcoholic During Protracted Abstinence: Putative Anti-Craving Implications. Addiction Research & Therapy, 5:1-7, 2014.
327. Blum K, Simpatico T, Waite R.,  Blum S, Dushaj K, Madigan M, Braverman, ER, Oscar-Berman, M.(2014) "Reward" Gene Polymorphisms May Predict High Rates of Injury and Addiction in the Workforce: a nutrient and electrotherapeutic based solution.  Health; Vol.6 No.16(2014), Article ID:49876,25 pagesDOI:10.4236/health.2014.616262
328. Blum K, Gold MS. “Depressed Dopamine Function is Attention- Deficit/Hyperactivity Disorder: Should Genotyping of Dopaminergic Polymorphisms Constitute Early Diagnosis in Children?” Pediatrics, Postgradmed 126(1):153-77.
329. Braverman ER, Han D., Oscar-Berman M,  Loehmann R, Dushaj D, Damle U, Blum K.  Multi-Hormonal Bio-identical Replacement Therapy Map (MHRT) in Menopause: Significant Associations as a Function of Somatic and Neurological Symptom Clusters PlosONe  2014 Sep 24;9(9):e105048. doi: 10.1371/journal.pone.0105048. eCollection 2014.
330. Blum K, Han D, Oscar-Berman M, Reinl G, DiNubile,N, Madigan MA, Bajaj A, Dows BW, Giordano J, Westcott W, Smith L, Braverman Er, Dushaj, Loehmann R, Hauser M, Simpatico T, McLaughlin T, Beley t, Borsten J, Barh D. Iatrogenic Opioid Dependence is Endemic and Legal: Coupling Genetic Addiction Risk Score (GARS) with Electrotherapy as a new paradigm shift in pain relief programs. Heath Vol.5, No.11A, 16-34 (2013) Health http://dx.doi.org/10.4236/health.o
331. Blum K , Han D, Madigan M, Loehmann R, Dushaj K, Braverman ER.“Cold” X5 Hairlaser™ used to treat male androgenic alopecia: Preliminary report trends significant hair growth. BMC-Research Notes. 7:103
332. . Blum K, Febo M, Mclaughlin T, Cronje F, Han D, Gold M. (2014) Hatching the behavioral addiction egg: Reward Deficiency Solution System (RDSS)™ as a function of dopaminergic neurogenetics and brain functional connectivity linking all addictions under a common rubric. Journal of Behavioral Addictions. Do1: 10.1556/jba.3.20.2014.019.
333. Blum K, Smith DE, Femini J, Roy AK, Simpatico T, Inaba D, Agan G, Frantantonio J, Febo M, Barh D. (2014) Hypothesizing benefits of the incorporation of genetic addiction risk (GARSRX™) and Dopamine Agonist Modalities (DAM) in clinical Addiction Medicine.  Journal of Addiction Therapy & Research. 1(2): 009.
334. Blum K, Oscar-Berman M, Jacobs W., McLaughlin T, Gold MS. (2014) Buprenorphine response as a function of neurogenetic polymorphic antecedents: Can dopamine genes affect clinical outcomes in Reward Deficiency Syndrome (RDS)? Addiction Research & Therapy. 5.3.
335. Blum K, Smith DE, Femino J, Roy AK. (2014) Clinical Integration of Innovative Genetic  Risk/Medical Monitoring in Reward Deficiency Syndrome(RDS). Presented at the 45th Annual ASAM meeting, Orlando Florida(won Best Abstract Lab Award).  
336. Blum K , Oscar-Berman M, Gardner EL, Simpatico T, Braverman ER, Gold MS. Neurogenetics &Neurobiology of Dopamine in  Anhedonia. In: Anhedonia: A Comprehensive Handbook (vol1) editor Ritsner M. Chapter 9 Springer, London, pp. 179-208.
337. Blum K, Femino J, Teitelbaum S, Giordano J, Oscar-Berman, Gold MS. (2013) “Molecular Neurobiology of Addiction Recovery: The 12 step program & Fellowship. Springer, New York.
338. Westcott, Aprovian CM, Corina L, Loud RL, Whitehead S, Blum K, DiNubile N(2013). Nutrition Programs Enhance Exercise effects on Body Composition and resting state blood pressure. The Physician  and Sportsmedicine. 41: 85-91.
339. Blum K., Han D, Hauser M, Downs BW, Giordano, J, Borsten J, Winchell E, Simpatico T, Madigan M, Barh D. (2013) Neurogenetic impairments of barin reward circuitry links to Reward Deficiency Syndrome(RDS) as evidenced by Genetic Addiction Risk Score(GARS): A case study. IIOAB 4L1)-4-9.
340. Blum K, Braverman ER, Kreuk F, Dushaj K, Li M, Barh D, Oscar-Berman M. (2014) Genome wise sequencing compared to candidate gene association studies for predisposition to substance abuse a subset of Reward Deficiency Syndrome (RDS) : Are we throwing the baby out with  bathwater?    Epidemiology 4(3) 1000158.
341. Blum K, Febo M, Thanos PK, Baron D, Gold MS. (2014).Clinically Combatting Reward Deficiency Syndrome (RDS) with Dopamine Agonist Therapy as a Paradigm Shift: Dopamine for Dinner? Mol Neurobiology 2015 Mar 10
342. Blum K & Rajendra Badgaiyan (2013) Addiction Research & Therapy in the 21st Century: Providing a Forum for Evidence –Based Addiction Medicine.: Jouranl of Addiction  Res & Therapy.Editorial. 3(1) ecollection  
343. Blum K, Badgaiyan R, Agan G, Fratantonio J, Gold MS (2014) Reward Deficiency Syndrome (RDS): Is there a Solution?. J Alcohol Drug Depend 2:177. doi: 10.4172/2329-6488.1000177.
344. Barh D, Jain N, Tiwari S, Field JK, Padin-Iruegas E, Ruibal A, López R, Herranz M, Bhattacharya A, Juneja L, Viero C, Silva A, Miyoshi A, Kumar A, Blum K, Azevedo V, Ghosh P, Liloglou T (2013). A novel in silico reverse-transcriptomics-based identification and blood-based validation of a panel of sub-type specific biomarkers in lung cancer. BMC Genomics. 2013;14 Suppl 6:S5. doi: 10.1186/1471-2164-14-S6-S5.
345. Braverman ER, Oscar-Berman M, Kreuk F, Kerner M, Dushaj K, Li M, Stratton D, Trudesdell C, Blum K. Preliminary Hormonal Correlations in Female Patients as a Function of Somatic and Neurological Symptom Clusters: An Exploratory Development of a Multi-Hormonal Map for Bio-Identical Replacement Therapy (MHRT).J Genet Syndr Gene Ther. 2013 Dec 6;4. pii: 206.
346. Blum K, Thanos PK, Gold MS. Dopamine and glucose, obesity, and reward deficiency syndrome.Front Psychol. 2014 Sep 17;5:919. doi: 10.3389/fpsyg.2014.00919. eCollection 2014.
347. Braverman ER, Han D, Oscar-Berman M, Karikh T, Truesdell C, Dushaj K, Kreuk F, Li M, Stratton D, Blum K. Menopause Analytical Hormonal Correlate Outcome Study (MAHCOS) and the Association to Brain Electrophysiology (P300) in a Clinical Setting. PLoS One. 2014 Sep 24;9(9):e105048.
348. Blum K, Han D, Femino J, Smith DE, Saunders S, Simpatico T, Schoenthaler SJ, Oscar-Berman M, Gold MS. Systematic evaluation of "compliance" to prescribed treatment medications and "abstinence" from psychoactive drug abuse in chemical dependence programs: data from the comprehensive analysis of reported drugs. PLoS One. 2014 Sep 23;9(9):e104275. doi: 10.1371/journal.pone.0104275. 
349. Blum K, Oscar-Berman M, Badgaiyan R, Braverman ER, Gold MS. Hypothesizing Darkness Induced Alcohol Intake Linked to Dopaminergic Regulation of Brain Function. Psychology (Irvine). 2014 Mar;5(4):282-288.
350. Blum K, Oscar-Berman M, Waite RL, Braverman ER, Kreuk F, Li M, Dushaj K, Madigan MA, Hauser M, Simpatico T, Barh D. A Multi-Locus Approach to Treating Fibromyalgia by Boosting Dopaminergic Activity in the Meso-Limbic System of the Brain.J Genet Syndr Gene Ther. 2014 Jan 27;5(1):213. 
351. Blum K, Rajendra D. Badgaiyan, Gold MS. Reward Defiicency Solution System (RDS): A Tale of Three  Scientists. Journal of Addiction Medicne & Theraprutic Science. 1(10:104, 2014).
352. Blum K, Smith DE, Femino J, Roy AK, Simpatico T, Inaba D, Agan G, Fratantonio, Febo M, Fornari F, Hauser M, Barh D.  Hypothesizing Benefits of the Incorporation of Genetic Addiction Risk Score (GARSRX™Rx™) and Dopamine Agonist Modalities (DAM) in Clinical Addiction Medicine.J Add Thpy. 2014, Volume 1, Issue 2: 009
353. Blum K, Liu Y, Wang W, Wang Y, Zhang Y, Oscar-Berman M, Smolen A, Febo M, Han D, Simpatico T, Cronjé FJ, Demetrovics Z, Gold MS. rsfMRI effects of KB220Z™ on neural pathways in reward circuitry of abstinent genotyped heroin addicts. .Postgrad Med. 2014 Dec 16:1-10.
354. Blum K, Oscar-Berman M, Jacobs W, McLaughlin T, Gold MS. Buprenorphine Response as a Function of Neurogenetic Polymorphic Antecedents: Can Dopamine Genes Affect Clinical Outcomes in Reward Deficiency Syndrome (RDS)? J Addict Res Ther. 2014;5. pii: 1000185.
355. Blum K, Oscar-Berman M, Badgaiyan RD, Khurshid KA, Gold MS. Dopaminergic Neurogenetics of Sleep Disorders in Reward Deficiency Syndrome (RDS).J Sleep Disord Ther. 2014 Feb 18;3(2):126.
356. Blum K, Braverman, ER, Waite RL, Archer T, Thanos PK, Badgaiyan RD, Febo M, Dushaj K, Li M, Gold MS. Neuroquantum Theories of Psychiatric Genetics: Can Physical Forces induce epigenetic influence on future genomes. Neuroquantology NeuroQuantology | March 2015 | Volume 13 | Issue 1 | Page 90-103
357. Blum K. (2015) Reward Deficiency Syndrome Solution System™ (RDSS): A 50 year sojourn. Journal of Behavioral Addictions. 4: (1) suppl 1-3.
358. Blum K, Badgaiyan RD, Gold MS. Reward Deficiency Syndrome (RDS) A Tale of Three Scientists. J Addiction Medicine & Therapeutic Science. 1(1) 104. 
359. Blum K and Badgaiyan RD (2015) Reward Deficiency Syndrome: Entering the Genomic & Neuroscience Era of Addiction Medicine .JRDS 1(1) : 1-2
360. Blum K, Badgaiyan RD, Anges D, Gold MS. (2015) Should we embrace vaccines for treating substance related disorder, a subset of Reward Deficiency Syndrome (RDS). JRDS 1(1) : 3-5.
361. Modestino EJ, Blum K, Oscar-Berman M, Gold MS, Duane DD, Sultan SG, Auerbach SH.(2015) Reward Deficiency Syndrome: Attentional/Arousal Subtypes: Limitations of Current Diagnostic Nosology, and Future Research. JRDS 1(1) : 6-9
362. Badgaiyan RD, Sinha S, Blum K. (2015) Do We Really Need to Continue Pharmacotherapy for Opioid Use Disorder Indefinitely? JRDS 1(1) :16-19.
363. Blum K, Oscar-Berman M, Braverman ER, Febo M, Li M, Gold MS. (2015) Enhancing Brain Pegnenolone May Protect Cannabis Intoxication but should not be considered as an Anti-Addiction Therapeutic: Hypothesizing Dopaminergic Blockade and Promoting Anti-Reward. JRDS 1(1) : 20-23.
364. McLaughlin T, Blum K, Oscar-Berman M, Febo M, Demetrovics Z, Gozde A, Fratantonio J,  Gold MS. (2015) Using the Neuroadaptagen KB220Z ™ to ameliorate  terrifying  Lucid Nightmares in PTSD/RDS Patients: Role of Enhanced, Brain-Reward, Functional Connectivity, and Dopaminergic Homeostasis. JRDS 1(1): 24-35.
365. Schoenthaler S, Blum K, Braverman ER, Giordano J, Thompson B, Oscar-Berman M, Badgaiyan RD, Madigan M, Dushaj K, Li M, Demetrovics Z,  Waite RL, MS Gold (2015) NIDA-Drug Addiction Treatment Outcome Study (DATOS) Relapse as a Function of Spirituality/Relgiosity. JRDS 1(1) : 36-45
366. Blum K, Thompson B, Demotrovics Z, Femino J, Giordano J, Oscar-Berman M, Teitlebaum S, Smith DE, Roy AK, Agan G, Fratantonio J, Badgaiyan RD,  Gold MS. (2015) The Molecular Neurobiology of the Twelve Steps Program & Fellowship: Connecting the Dots for Recovery. JRDS 1(1) :46-64.
367. Blum K, Badgaiyan RD,  Agan G, Fratantonio J, Simpatico T, Febo M, Haberstick BC, Smolen A, Gold MS. (2015)  Molecular Genetic Testing in Reward Deficiency Syndrome (RDS): Facts and Fiction. JRDS 1(1) : 65-68
368. Roger L Waite, Marlene Oscar-Berman, Eric R Braverman, Debmalya Barh and Kenneth Blum(2014)Quantitative Electroencephalography Analysis (qEEG) of Neuro-Electro- Adaptive Therapy 12™ [NEAT12] Up-Regulates Cortical Potentials in an Alcoholic during Protracted Abstinence: Putative Anti-Craving Implications. Case Report:  J Addict Res Ther 2014, 5: 171.
369. McLaughlin T, Blum K, Oscar-Berman M, Febo M, Agan G, Fratantonio J, Simpatico T,, Gold MS (2015). Putative dopamine agonist (KB220Z) attenuates lucid dreams in PTSD patients: Role of enhanced brain reward functional connectivity and homeostasis redeeming joy. J Behav Addict.  4(2): 106-15.
370. Blum K, Thanos PK, Badgaiyan RD, Febo M, Oscar-Berman M, Fratantonio J, Demotrovics Z, Gold MS (2015).Neurogenetics and gene therapy for Reward Deficiency Syndrome: are we going to the promised land. Exp Opin Biol Ther 15(7): 973.
371. Blum K, Febo M, Smith DE, Roy AK 3rd, Demetrovics Z, Cronjé FJ, Femino J, Agan G, Fratantonio JL, Pandey SC, Badgaiyan RD, Gold MS (2015). Neurogenetic and epigenetic correlates of adolescent predisposition to and risk for addictive behaviors as a function of prefrontal cortex dysregulation. J Child Adolesc Psychopharmacol.25(4):286-92

1. Braverman ER, Blum K, Hausman K. et al. Evoked Potentials and Memory/Cognition Tests Validate Brain Atrophy as Measured by 3T MRI (NeuroQuant®) in Cognitively Impaired Patients
   PLOS ONE 10(8):e0133609. 

1. Gold MS, Badgaiyan RD, and Blum K  (2015) A shared Molecular and Genetic Basis for Food & Drug Addiction: Overcoming Hypodopaminergic Trait/Sate by Incorporating Dopamine Agonistic Therapy in Psychiatry. Psych. Clin N Am. 38(3):419-62. 

1. Blum K, Badgaiyan RD, Gold MS(2015). Hypersexuality Addiction and Withdrawal: Phenomenology, Neurogenetics and Epigenetics. Cureus. 2015 Oct 12;7(10):e348.

1. Barh D, Kamapantula B, Jain N, Nalluri J, Bhattacharya A, Juneja L, Barve N, Tiwari S, Miyoshi A, Azevedo V, Blum K, Kumar A, Silva A, Ghosh P (2015). miRegulome: a knowledge-base of miRNA regulomics and analysis. Sci Rep. 5:12832.

1. Blum K, Badgaiyan RD, Demotrovics Z, Fratantonio J, Agan G, Febo M (2015). Can Genetic Testing Provide Information to Develop Customized Nutrigenomic Solutions for Reward Deficiency Syndrome?Clin Med Rev Case Rep. 2015;2(1). pii: 018.
2. McLaughlin T, Blum K, Oscar-Berman M, Febo M, Agan G, Fratantonio JL, Simpatico T, Gold MS (2015). Putative dopamine agonist (KB220Z) attenuates lucid nightmares in PTSD patients: role of enhanced brain reward functional connectivity and homeostasis redeeming joy. J Behav Addict. 4(2):106-15.
3. Blum K, Thanos PK, Oscar-Berman M, Febo M, Baron D, et al. 2015. Dopamine in the Brain: Hypothesizing Surfeit or Deficit Links to Reward and Addiction. J Reward Defic Syndr 1(3): 95-104.
4. Miller D, Miller M, Blum K, Badgaiyan RD, Febo M. 2015. Addiction Treatment in America: After Money or Aftercare? J Reward Defic Syndr 1(3): 87-94.
5.  Blum K, Simpatico T, Badgaiyan RD, Demetrovics Z, Fratantonio J, et al. 2015. Coupling Neurogenetics (GARS™) and a Nutrigenomic Based Dopaminergic Agonist to Treat Reward Deficiency Syndrome (RDS): Targeting Polymorphic Reward Genes for Carbohydrate Addiction Algorithms. J Reward Defic Syndr 1(2): 75-80.
6. Blum K, Febo M, Fahlke C, Archer T, Berggren U, Demetrovics Z, Dushaj K, Badgaiyan RD. Hypothesizing Balancing Endorphinergic and Glutaminergic Systems to Treat and Prevent Relapse to Reward Deficiency Behaviors: Coupling D-Phenylalanine and N-Acetyl-L-Cysteine (NAC) as a Novel Therapeutic Modality. Clin Med Rev Case Rep. 2015;2(8). pii: 076.
7. Miller D, Miller M, Blum K, Badgaiyan RD, Febo M. Addiction Treatment in America: After Money or Aftercare? J Reward Defic Syndr. 2015 Oct 21;1(3):87-94.
8. Blum K, Hauser M, Fratantonio J, Badgaiyan RD. Molecular Genetic Testing in Pain and Addiction: Facts, Fiction and Clinical Utility. Addict Genet. 2015 Jul 1;2(1):1-5. Epub 2015 Aug 28.
9. Blum K, Oscar-Berman M, Braverman ER, Febo M, Li M, Gold MS. Enhancing Brain Pregnenolone May Protect Cannabis Intoxication but Should Not Be Considered as an Anti-addiction Therapeutic: Hypothesizing Dopaminergic Blockade and Promoting Anti-Reward.J Reward Defic Syndr. 2015;1(1):20-23.
10. Colon-Perez LM, Tran K, Thompson K, Pace MC, Blum K, Goldberger BA, Gold MS, Bruijnzeel AW, Setlow B, Febo M. The Psychoactive Designer Drug and Bath Salt Constituent MDPV Causes Widespread Disruption of Brain Functional Connectivity.Neuropsychopharmacology. 2016 Mar 21. doi: 10.1038/npp.2016.40.
11. Thanos PK, Hamilton J, O'Rourke JR, Napoli A, Febo M, Volkow ND, Blum K, Gold M. Dopamine D2 gene expression interacts with environmental enrichment to impact lifespan and behavior. Oncotarget. 2016 Mar 15. doi: 10.18632/oncotarget.8088.
12. Blum K, Febo M, Badgaiyan RD, Braverman ER, Dushaj K, Li M, You S, Demetrovics Z.(2016). Neuronutrient Amino-Acid Therapy Protects Against Reward Deficiency Syndrome: Dopaminergic Key to Homeostasis and Neuroplasticity. Curr Pharm Des. 2016 Jul 19.
13. Beitscher-Campbell H, Blum K, Febo M, Madigan MA, Giordano J, Badgaiyan RD, Braverman ER, Dushaj K, Li M, Gold MS.(2016). Pilot clinical observations between food and drug seeking derived from fifty cases attending an eating disorder clinic. J Behav Addict. 2016 Aug 9:1-9. 
14. Blum K, Gold M, Clark HW, Dushaj K, Badgaiyan RD (2016). Should the United States Government Repeal Restrictions on Buprenorphine/Naloxone Treatment? Subst Use Misuse. 2016 Jul 27:1-6.
15. Blum K, Simpatico T, Febo M, Rodriquez C, Dushaj K, Li M, Braverman ER, Demetrovics Z, Oscar-Berman M, Badgaiyan RD (2016). Hypothesizing Music Intervention Enhances Brain Functional Connectivity Involving Dopaminergic Recruitment: Common Neuro-correlates to Abusable Drugs. Mol Neurobiol. 2016 May 31.
16. Blum K, Febo M, Badgaiyan RD, Demetrovics Z, Simpatico T, Fahlke C, Oscar-Berman M, Li M, Dushaj K, Gold MS (2016), Common Neurogenetic Diagnosis and Meso-Limbic Manipulation of Hypodopaminergic Function in Reward Deficiency Syndrome (RDS): Changing the Recovery Landscape. Curr Neuropharmacol. 2016 May 12. 
17. Blum K, Febo M, Fahlke C, Archer T, Berggren U, Demetrovics Z, Dushaj K, Badgaiyan RD (2016). Hypothesizing Balancing Endorphinergic and Glutaminergic Systems to Treat and Prevent Relapse to Reward Deficiency Behaviors: Coupling D-Phenylalanine and N-Acetyl-L-Cysteine (NAC) as a Novel Therapeutic Modality. Clin Med Rev Case Rep. 2015;2(8). pii: 076.
18. Blum K, Febo M, Badgaiyan RD, Braverman ER, Dushaj K, Li M, You S, Demetrovics Z.(2016). Neuronutrient Amino-Acid Therapy Protects Against Reward Deficiency Syndrome: Dopaminergic Key to Homeostasis and Neuroplasticity. Curr Pharm Des. 2016 Jul 19.
19. K. Blum, D. Han, M. Oscar-Berman, D. E. Smith, S. Suanders,  J. Femino, T. Simpatico,  A. K.Roy,111, W. Jacobs, D. Inaba, J. Fratantonio, G Agan, MS. Gold (2014) Quantitative analysis of compliance to Suboxone and abstinence to drugs of abuse utilizing the Comprehensive Analysis of Reported Drugs (CARD): Significant Attenuation of Illicit Opioid Abuse during Treatment ( submitted to Substance Use Misuse)
20. Blum K, Haberstick,BC, Smolen A, Han D, Oscar-Berman M, Smith DE, Simpatico T, Borsten J, Winchel E, Giordano J, Jones S., Braveman Er, Dushaj K, Li M, Hauser M, Campenella C, Femino J, Villapiano A, Butler S, Roy AK, Cook H. McCormick L, Lindsey C, McLaughlin T, Jaffe A, Holiday B, Barh D, Agan G, Frantantonio JL, Marzilli L, Cronjé, F, Demetrovics Z, Baron D, Gold MS (2015). Quantification of Addiction Risk Utilizing the Genetic Addiction Risk Score (GARSRX™) in Multiple- Treatment Centers in the United States: Prediction of Addiction Severity Index-Alcohol- Risk Sore, Family History and Illicit Drug Abuse. To be submitted to Plosone
21. Febo M, Blum K, Badgaiyan RD, Perez, PD, Colon-Perez LM, Thanos PK, Ferris CF, Kulkarni P, Giordano J, Baron D, Gold MS (2015). KB220Z complex™ enhances resting state brain reward circuit functional connectivity (rsfMRI) and connectivity volume: Are we targeting “Dopamine Homeostasis.”?  Submitted to PlosONe (in revision)
22. Kenneth Blum , B.W. Downs , Kristina Dushaj  , Mona Li , Eric R. Braverman , Lyle Fried , Roger Waite , Zsolt Demotrovics , Rajendra D. Badgaiyan. THE BENEFITS OF CUSTOMIZED DNA DIRECTED NUTRITION TO BALANCE THE BRAIN REWARD CIRCUITRY AND REDUCE ADDICTIVE BEHAVIORS. Precision Medicine Journal. 1(1): 18-33(2016).
23. Steinberg B, Blum K, McLaughlin T, Lubar J, Febo M, Braverman ER, Badgaiyan RD. Low-Resolution Electromagnetic Tomography (LORETA) of changed Brain Function Provoked by Pro-Dopamine Regulator (KB220z) in one Adult ADHD case. Open J Clin Med Case Rep. 2016;2(11). pii: 1121.
24. Marcelo Febo, Kenneth Blum, Rajendra D. Badgaiyan, David Baron, Panayotis K. Thanos, Luis M. Colon-Perez, Zsolt Demotrovics, Mark S. Gold. ‘Dopamine homeostasis’ and its implications for Brain Network Connections in  Reward Deficiency Syndrome. Frontiers of Bioscience (in Press 2016).
25. Kenneth Blum, Debra Whitney, Lye Fried, Marcelo Febo, Roger L Waite, Eric R. Braverman,  Kristina Dushaj, Mona Li, John Giordano,  Zsolt Demetrovics, Rajendra D. Badgaiyan. Hypothesizing that a Pro-Dopaminergic Regulator (KB220z™ Liquid Variant) Can Induce “Dopamine Homeostasis” and Provide Adjunctive Detoxification Benefits in Opiate/Opioid Dependence. Clin Med. Rev. & Case Reports (in Press 2016).
26. Kenneth Blum,  Mark S Gold, William Jacobs, W. Vaughn McCall, Marcelo Febo, David Baron, Kristina Dushaj, Zsolt Demetrovics, and Rajendra D. Badgaiyan. Neurogenetics of acute & chronic opiate/opioid abstinence: treating symptoms & the cause. Frontiers of Bioscience (in Press 2016).
27. Schoenthaler SJ, Blum K, Badgaiyan RD, Oscar-Berman M, Giordano J, Simpatico T. (2016) The effects of residential dual diagnosis treatment on alcohol abuse . Am Journal of Addiction (in revision)
28. Kenneth Blum, Marcelo Febo, Kristina Dushaj, FLyle Fried, Rajendra D. Badgaiyan. “Pro-Dopamine Regulation (KB220Z™)” as a Long-Term Therapeutic Modality to Overcome Reduced Resting State Dopamine Tone in Opiate /Opioid Epidemic in America. Journal of Systems & Integrative Neuroscience.(in press).
29. Blum K , Atzman G, Baron D, Badgaiyan RD. Hypothesizing molecular genetics of the Holocaust: Were dopaminergic genes involved or brain wash? SOJ Psychology. 3(1) :1-5, 2016.
30. Blum K, Febo M, Badgaiyan RD. Fifty Years in the Development of a Glutaminergic-Dopaminergic Optimization Complex (KB220) to Balance Brain Reward Circuitry in Reward Deficiency Syndrome: A Pictorial. Austin Addict Sci. 2016;1(2). pii: 1006.